<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html id="nojs" xmlns="http://www.w3.org/1999/xhtml" xmlns:m="http://www.w3.org/1998/Math/MathML" xmlns:og="http://ogp.me/ns#" xml:lang="en-GB" lang="en-GB" xmlns:wb=“http://open.weibo.com/wb”>

<head>

   
  
      
  
                  
  
                  
  
            
  
            
            
    <title>Trials | Full text | Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial</title>
<link rel="shortcut icon" type="image/x-icon" href="/images/icon/10096/favicon.ico" />
<link rel="apple-touch-icon" sizes="72x72" href="/sites/10096/images/70.gif" />
<meta http-equiv="X-UA-Compatible" content="IE=7" />


                
    
		
		
		
		
<!-- <?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:cc="http://web.resource.org/cc/" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">
<cc:Work rdf:about="http://www.trialsjournal.com/content/16/1/77">
<cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
</cc:Work>
<cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
<cc:permits rdf:resource="http://web.resource.org/cc/Reproduction"/>
<cc:permits rdf:resource="http://web.resource.org/cc/Distribution"/>
<cc:requires rdf:resource="http://web.resource.org/cc/Notice"/>
<cc:requires rdf:resource="http://web.resource.org/cc/Attribution"/>
<cc:permits rdf:resource="http://web.resource.org/cc/DerivativeWorks"/>
</cc:License>
<item rdf:about="http://www.trialsjournal.com/content/16/1/77">
<title>Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial</title>
<dc:title>Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial</dc:title>
<dc:creator>Kingsbury, Sarah R</dc:creator>
<dc:creator>Tharmanathan, Puvan</dc:creator>
<dc:creator>Arden, Nigel K</dc:creator>
<dc:creator>Batley, Michael</dc:creator>
<dc:creator>Birrell, Fraser</dc:creator>
<dc:creator>Cocks, Kim</dc:creator>
<dc:creator>Doherty, Michael</dc:creator>
<dc:creator>Edwards, Chris J</dc:creator>
<dc:creator>Garrood, Toby</dc:creator>
<dc:creator>Grainger, Andrew J</dc:creator>
<dc:creator>Green, Michael</dc:creator>
<dc:creator>Hewitt, Catherine</dc:creator>
<dc:creator>Hughes, Rod</dc:creator>
<dc:creator>Moots, Robert</dc:creator>
<dc:creator>O’Neill, Terence W</dc:creator>
<dc:creator>Roddy, Edward</dc:creator>
<dc:creator>Scott, David L</dc:creator>
<dc:creator>Watt, Fiona E</dc:creator>
<dc:creator>Torgerson, David J</dc:creator>
<dc:creator>Conaghan, Philip G</dc:creator>
<dc:identifier>info:doi/10.1186/s13063-015-0602-8</dc:identifier>
<dc:source>Trials 2015, 16:77</dc:source>
<dc:date>2015-03-04</dc:date>

<prism:publicationName>Trials</prism:publicationName>
<prism:publicationDate>2015-03-04</prism:publicationDate>
<prism:volume>16</prism:volume>
<prism:number>1</prism:number>
<prism:section>Study protocol</prism:section>
<prism:startingPage>77</prism:startingPage>
<prism:copyright>2015 Kingsbury et al.; licensee BioMed Central.</prism:copyright>
</item>
</rdf:RDF>
 -->
 
 
<meta name="citation_journal_title" content="Trials" />
<meta name="citation_publisher" content="BioMed Central Ltd" />


<meta name="citation_author" content="Sarah R Kingsbury" />
<meta name="citation_author_institution" content="Leeds Institute of Rheumatic and Musculoskeletal Medicine and National Institute of Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Chapeltown Road, Leeds LS7 4SA, UK" />
<meta name="citation_author" content="Puvan Tharmanathan" />
<meta name="citation_author_institution" content="York Trials Unit, Department of Health Sciences, Faculty of Science, Seebohm Rowntree Building, University of York, Heslington, York YO10 5DD, UK" />
<meta name="citation_author" content="Nigel K Arden" />
<meta name="citation_author_institution" content="NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, University of Oxford, Windmill Road, Headington, Oxford OX3 7LD, UK" />
<meta name="citation_author" content="Michael Batley" />
<meta name="citation_author_institution" content="Department of Rheumatology, Maidstone and Tunbridge Wells NHS Trust, Pembury, Tunbridge Wells TN2 4QJ, Kent, UK" />
<meta name="citation_author" content="Fraser Birrell" />
<meta name="citation_author_institution" content="Musculoskeletal Research Group, Institute for Cellular Medicine, Newcastle University, Musculoskeletal Research Group, 4th Floor Catherine Cookson Building, The Medical School, Framlington Place, Newcastle University, Newcastle NE2 4HH, UK" />
<meta name="citation_author" content="Kim Cocks" />
<meta name="citation_author_institution" content="York Trials Unit, Department of Health Sciences, Faculty of Science, Seebohm Rowntree Building, University of York, Heslington, York YO10 5DD, UK" />
<meta name="citation_author" content="Michael Doherty" />
<meta name="citation_author_institution" content="Academic Rheumatology, Clinical Sciences Building, University of Nottingham, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1 PB, UK" />
<meta name="citation_author" content="Chris J Edwards" />
<meta name="citation_author_institution" content="Department of Rheumatology and NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK" />
<meta name="citation_author" content="Toby Garrood" />
<meta name="citation_author_institution" content="Guy’s and St Thomas’ Hospitals Foundation NHS Trust, Great Maze Pond, London SE1 9RT, UK" />
<meta name="citation_author" content="Andrew J Grainger" />
<meta name="citation_author_institution" content="Leeds Institute of Rheumatic and Musculoskeletal Medicine and National Institute of Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Chapeltown Road, Leeds LS7 4SA, UK" />
<meta name="citation_author" content="Michael Green" />
<meta name="citation_author_institution" content="The York Hospital, York Hospitals NHS Foundation Trust, Wigginton Road, York YO31 8HE, UK" />
<meta name="citation_author" content="Catherine Hewitt" />
<meta name="citation_author_institution" content="York Trials Unit, Department of Health Sciences, Faculty of Science, Seebohm Rowntree Building, University of York, Heslington, York YO10 5DD, UK" />
<meta name="citation_author" content="Rod Hughes" />
<meta name="citation_author_institution" content="Rheumatology Department, St Peters Hospital, Guildford Road, Chertsey KT16 0PZ, Surrey, UK" />
<meta name="citation_author" content="Robert Moots" />
<meta name="citation_author_institution" content="Institute of Integrative Biology, University of Liverpool and Institute of Ageing and Chronic Disease, University Hospital Aintree, Longmoor Lane, Fazakerley, Liverpool L9 7AL, Merseyside, UK" />
<meta name="citation_author" content="Terence W O’Neill" />
<meta name="citation_author_institution" content="Arthritis Research UK Centre for Epidemiology, The University of Manchester, 2nd floor, Stopford Building, Oxford Road, Manchester M13 9PT, UK" />
<meta name="citation_author" content="Edward Roddy" />
<meta name="citation_author_institution" content="Research Institute for Primary Care and Health Sciences, Keele University, Keele ST5 5BG, Staffordshire, UK" />
<meta name="citation_author" content="David L Scott" />
<meta name="citation_author_institution" content="Department of Rheumatology, King’s College London School of Medicine, King’s College London and Department of Rheumatology, King’s College Hospital, 10 Cutcombe Road, London SE5 9RJ, London, UK" />
<meta name="citation_author" content="Fiona E Watt" />
<meta name="citation_author_institution" content="Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road, Oxford, OX3 7HE, UK and Imperial College London, South Kensington Campus, London SW7 2AZ, UK" />
<meta name="citation_author" content="David J Torgerson" />
<meta name="citation_author_institution" content="York Trials Unit, Department of Health Sciences, Faculty of Science, Seebohm Rowntree Building, University of York, Heslington, York YO10 5DD, UK" />
<meta name="citation_author" content="Philip G Conaghan" />
<meta name="citation_author_institution" content="Leeds Institute of Rheumatic and Musculoskeletal Medicine and National Institute of Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Chapeltown Road, Leeds LS7 4SA, UK" />


<meta name="citation_issn" content="1745-6215" />
<meta name="citation_title" content="Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial" />
<meta name="citation_volume" content="16" />
<meta name="citation_issue" content="1" />
<meta name="citation_date" content="2015-03-04" />
<meta name="citation_firstpage" content="77" />
<meta name="citation_doi" content="10.1186/s13063-015-0602-8" />
<meta name="citation_pdf_url" content="http://www.trialsjournal.com/content/pdf/s13063-015-0602-8.pdf" />
<link rel="alternate" type="application/pdf" title="PDF" href="http://www.trialsjournal.com/content/pdf/s13063-015-0602-8.pdf" />
<meta name="title" content="Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial" />
<meta name="description" content="Osteoarthritis (OA) is the fastest growing cause of disability worldwide. Current treatments for OA are severely limited and a large proportion of people with OA live in constant, debilitating pain. There is therefore an urgent need for novel treatments to reduce pain. Synovitis is highly prevalent in OA and is associated with pain. In inflammatory arthritides such as rheumatoid arthritis, methotrexate (MTX) is the gold standard treatment for synovitis and has a well-known, acceptable toxicity profile. We propose that using MTX to treat patients with symptomatic knee OA will be a practical and safe treatment to reduce synovitis and, consequently, pain." />

<meta name="dc.title" content="Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial" />
<meta name="dc.creator" content="Kingsbury, Sarah R" />
<meta name="dc.creator" content="Tharmanathan, Puvan" />
<meta name="dc.creator" content="Arden, Nigel K" />
<meta name="dc.creator" content="Batley, Michael" />
<meta name="dc.creator" content="Birrell, Fraser" />
<meta name="dc.creator" content="Cocks, Kim" />
<meta name="dc.creator" content="Doherty, Michael" />
<meta name="dc.creator" content="Edwards, Chris J" />
<meta name="dc.creator" content="Garrood, Toby" />
<meta name="dc.creator" content="Grainger, Andrew J" />
<meta name="dc.creator" content="Green, Michael" />
<meta name="dc.creator" content="Hewitt, Catherine" />
<meta name="dc.creator" content="Hughes, Rod" />
<meta name="dc.creator" content="Moots, Robert" />
<meta name="dc.creator" content="O’Neill, Terence W" />
<meta name="dc.creator" content="Roddy, Edward" />
<meta name="dc.creator" content="Scott, David L" />
<meta name="dc.creator" content="Watt, Fiona E" />
<meta name="dc.creator" content="Torgerson, David J" />
<meta name="dc.creator" content="Conaghan, Philip G" />
<meta name="dc.description" content="Osteoarthritis (OA) is the fastest growing cause of disability worldwide. Current treatments for OA are severely limited and a large proportion of people with OA live in constant, debilitating pain. There is therefore an urgent need for novel treatments to reduce pain. Synovitis is highly prevalent in OA and is associated with pain. In inflammatory arthritides such as rheumatoid arthritis, methotrexate (MTX) is the gold standard treatment for synovitis and has a well-known, acceptable toxicity profile. We propose that using MTX to treat patients with symptomatic knee OA will be a practical and safe treatment to reduce synovitis and, consequently, pain." />
<meta name="dc.source" content="Trials 2015 16:77" />
<meta name="dc.format" content="text/html" />
<meta name="dc.publisher" content="BioMed Central Ltd" />
<meta name="dc.date" content="2015-03-04" />
<meta name="dc.type" content="Study protocol" />
<meta name="dc.identifier" content="10.1186/s13063-015-0602-8" />
<meta name="dc.language" content="en" />
<meta name="dc.copyright" content="2015 Kingsbury et al.; licensee BioMed Central." />
<meta name="dc.rights" content="http://creativecommons.org/licenses/by/2.0/" />
<meta name="dc.rightsAgent" content="reprints@biomedcentral.com" />

<meta name="prism.issn" content="1745-6215" />
<meta name="prism.publicationName" content="Trials" />
<meta name="prism.publicationDate" content="2015-03-04" />
<meta name="prism.volume" content="16" />
<meta name="prism.number" content="1" />
<meta name="prism.section" content="Study protocol" />
<meta name="prism.startingPage" content="77" />
<meta name="prism.copyright" content="2015 Kingsbury et al.; licensee BioMed Central." />
<meta name="prism.rightsAgent" content="reprints@biomedcentral.com" />


        <meta name="citation_abstract_html_url" content="http://www.trialsjournal.com/content/16/1/77/abstract" />
            <meta name="citation_fulltext_html_url" content="http://www.trialsjournal.com/content/16/1/77" />
            <link rel='alternate' type='text/xml' title='XML version' href='http://www.trialsjournal.com/content/download/xml/s13063-015-0602-8.xml' />
            <link rel="image_src" href="http://www.trialsjournal.com/content/figures/s13063-015-0602-8-toc.gif" />
    
    
    
    
                    
    

<script type="text/javascript">
// must run before css
document.documentElement.id = "js";
</script>



						
   
  
      
  
                  
  
                  
  
            
  
            
            



						
        <script type="text/javascript" src="http://www.bmcimg.com/javascript/plugins/jquery-1.8.2.min-0.js"></script>

	                <link rel="stylesheet" type="text/css" href="/css/main-0.css" media="screen, print"/>
    
                <link rel="stylesheet" type="text/css" href="/css/plugins-0.css" media="screen, print"/>
    



    

			                <link rel="stylesheet" type="text/css" href="http://www.bmcimg.com/css/articles-0.css" media="screen, print"/>
    	

    

    <link rel="stylesheet" type="text/css" href="/css/themes/10096.css" media="screen, print"/>


                <link rel="stylesheet" type="text/css" href="/css/media/print-0.css" media="print"/>
    



<!--[if IE]>
                    <link rel="stylesheet" type="text/css" href="/css/hacks/ie-0.css"/>
    <![endif]-->

<!--[if IE 7]>
                    <link rel="stylesheet" type="text/css" href="/css/hacks/ie7-0.css"/>
    <![endif]-->
			
<script type="text/javascript">
    //configuration
    OAS_url = '//oas.biomedcentral.com/RealMedia/ads/';

	// control of advert's position on page [AMC]
    
    	
	
    OAS_sitepage = "trialsjournal.com/article/10.1186/s13063/015/0602/8";
    	
		OAS_listpos = 'Top,x96,Right3';
	
	
			
		OAS_query = '';
		
	

    OAS_target = '_top';
    //end of configuration
    OAS_version = 10;
    OAS_rn = '001234567890'; OAS_rns = '1234567890';
    OAS_rn = new String (Math.random()); OAS_rns = OAS_rn.substring (2, 11);
    function OAS_NORMAL(pos) {
		document.write('<a href="' + OAS_url + 'click_nx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '!' + pos + '?' + OAS_query + '" target="' + OAS_target + '">');
		document.write('<img src="' + OAS_url + 'adstream_nx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '!' + pos + '?' + OAS_query + '" border="0"/></a>');
    }
    
	function refererTerms(referer) {

	if(referer.match("q=") != null) {
		referer = referer.split("q=");
		referer = referer[1].split("&");
		referer = referer[0];
	} else {
		referer = referer;
	}

		if(referer.match("%20") != null && referer.match("%20").length >= 1) {
			referer =  referer.replace(/%20/gi,"+");
			return referer;
		} else { 
			return referer; 
		}
	}
 </script>


 <script type="text/javascript">
	// Set the version of JavaScript to 10 for a Browser 'Mozilla/3' on webTV 
    OAS_version = 11;
    if ((navigator.userAgent.indexOf('Mozilla/3') != -1) || (navigator.userAgent.indexOf('Mozilla/4.0 WebTV') != -1)) {
     OAS_version = 10; }
    if (OAS_version >= 11) {
    document.write('<scr' + 'ipt type="text/javascript" src="' + OAS_url + 'adstream_mjx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '?' + OAS_query + '"><\/script>'); }
</script>
	
<script type="text/javascript">
    document.write('');
	
    function OAS_AD(pos) {
        if (OAS_version >= 11)
         OAS_RICH(pos);
        else
         OAS_NORMAL(pos);
    }
 </script>
	





<script type="text/javascript">
    jsonLoaders = function(){
        var _loaders = [];
        return {
            register: function(config){
                config.prefix = config.prefix || '/webapi/1.0/blogs/';
                config.feedLength = config.feedLength || 3;

                _loaders.push(config);
            },
            list: function(){return _loaders}
        };
    }();

    function totext() {
	    document.write('<a href="javascript:returnToText();">Return to text</a>');
    }

    function retrieve_doi(){
        var metas = document.getElementsByTagName('meta');
        var i;
        for (i = 0; i < metas.length; i++)
            if (metas[i].getAttribute('name') == "citation_doi")
                break;
        var citation_doi = metas[i].getAttribute('content');
        return citation_doi;
    }

</script>





    <script src="http://tjs.sjs.sinajs.cn/open/api/js/wb.js" type="text/javascript" charset="utf-8"></script>
        <link title="Latest articles" rel="alternate" href="http://www.trialsjournal.com/latest/rss" type="application/rss+xml" exposeToHeader="true"/>
    <link title="Most viewed" rel="alternate" href="http://www.trialsjournal.com/mostviewed/rss/" type="application/rss+xml" exposeToHeader="true"/>
    <link title="Latest comments" rel="alternate" href="http://www.trialsjournal.com/latestcomments/rss" type="application/rss+xml" exposeToHeader="true"/>
    


	<script type="text/javascript">
	var _gaq = _gaq || [];
	_gaq.push(['_setAccount', 'UA-9663741-5']);
	_gaq.push(['_gat._anonymizeIp']);
	_gaq.push(['_setLocalRemoteServerMode']);
	
	/*for cross domain tracking*/
	//_gaq.push(['_setAllowLinker', true]);
    //_gaq.push(['_setDomainName', 'trialsjournal.com']); //this journal's domain
	/**/
	
		_gaq.push(['_trackPageview']); 

	(function() {
		var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
		ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
		var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);

		//var iframe = document.getElementById('casesdb-search-widget');
		//if(iframe !== null) {
		//	var pageTracker = _gat._getTrackerByName();
		//	iframe.src = pageTracker._getLinkerUrl('http://www.casesdatabase.com/');
		//}
	})();
	</script>

	
        </head>


<body class=" theme    ">


        



   
  
      
  
                  
  
                  
  
            
  
            
            

    

<div id="oas-campaign" style="display:none">trialsjournal.com/article/10.1186/s13063/015/0602/8</div>
<div id="oas-positions" style="display:none">Bottom,Top</div>

<div id="branding" role="banner">
                			
		<dl class="google-ad wide ">
	<dt class="hide">
					<a class="banner-ad" href="http://www.biomedcentral.com/advertisers/digital_advertising"></a>
				
			</dt>
		<dd>

		<!-- OAS AD 'Top' begin -->
		<script type="text/javascript">
		OAS_AD('Top');

		</script>
		<!-- OAS AD 'Top' end -->
		</dd>

		</dl>

		<noscript>
			<dl class="google-ad wide noscript">  
    <dt class="hide"></dt>
    
    <dd>
        <a href="//oas.biomedcentral.com/RealMedia/ads/click_nx.ads/trialsjournal.com/article/10.1186/s13063/015/0602/8/15116124610@Top?">
            <img src="//oas.biomedcentral.com/RealMedia/ads/adstream_nx.ads/trialsjournal.com/article/10.1186/s13063/015/0602/8/15080190182@Top?" alt="advert"/>
        </a>
    </dd>
			</dl>
		</noscript>
			            <div class="sup-panel-outer">
        <div class="sup-panel-inner">

            <style>
  #nojs li.greeting, #nojs li#loginLink {display:none;}
</style>


<ul id="login" class="login">

    <noscript><li><a href="/log"><img class="greeting" src="/images/log.gif"/></a></li></noscript>
    
    <li id="welcome"><span id="username"></span></li>

    <li id="loginLink"><a href=""></a></li>
    
    
</ul>

<script>

function login() {

/* cookie getter/setter */
var allCookies = {
  getItem: function (sKey) {
    if (!sKey || !this.hasItem(sKey)) { return null; }
    return unescape(document.cookie.replace(new RegExp("(?:^|.*;\\s*)" + escape(sKey).replace(/[\-\.\+\*]/g, "\\$&") + "\\s*\\=\\s*((?:[^;](?!;))*[^;]?).*"), "$1"));
  },
  setItem: function (sKey, sValue, vEnd, sPath, sDomain, bSecure) {
    if (!sKey || /^(?:expires|max\-age|path|domain|secure)$/i.test(sKey)) { return; }
    var sExpires = "";
    if (vEnd) {
      switch (vEnd.constructor) {
        case Number:
          sExpires = vEnd === Infinity ? "; expires=Tue, 19 Jan 2038 03:14:07 GMT" : "; max-age=" + vEnd;
          break;
        case String:
          sExpires = "; expires=" + vEnd;
          break;
        case Date:
          sExpires = "; expires=" + vEnd.toGMTString();
          break;
      }
    }
    document.cookie = escape(sKey) + "=" + escape(sValue) + sExpires + (sDomain ? "; domain=" + sDomain : "") + (sPath ? "; path=" + sPath : "") + (bSecure ? "; secure" : "");
  },
  removeItem: function (sKey, sPath) {
    if (!sKey || !this.hasItem(sKey)) { return; }
    document.cookie = escape(sKey) + "=; expires=Thu, 01 Jan 1970 00:00:00 GMT" + (sPath ? "; path=" + sPath : "");
  },
  hasItem: function (sKey) {
    return (new RegExp("(?:^|;\\s*)" + escape(sKey).replace(/[\-\.\+\*]/g, "\\$&") + "\\s*\\=")).test(document.cookie);
  },
  keys: /* optional method: you can safely remove it! */ function () {
    var aKeys = document.cookie.replace(/((?:^|\s*;)[^\=]+)(?=;|$)|^\s*|\s*(?:\=[^;]*)?(?:\1|$)/g, "").split(/\s*(?:\=[^;]*)?;\s*/);
    for (var nIdx = 0; nIdx < aKeys.length; nIdx++) { aKeys[nIdx] = unescape(aKeys[nIdx]); }
    return aKeys;
  }
};

// converts cookie into js object
function parseCookie(cookie) {

    cookie = cookie.split("&");
    var obj = {};

    for(var i = 0; i < cookie.length; i++) {

        var c = cookie[i].split("=");

        c[0] = c[0].replace('"','');
        
        obj[c[0]] = c[1];

    }
    return obj;
}

    var cookie = allCookies.getItem("bmccookie");

    var obj = (cookie != null) ? parseCookie(cookie) : {};
    

        var welcome = "";

        if(obj.hasOwnProperty("fname")) {

            // insert user welcome
            welcome = obj.fname.replace(/\+/g, " ") + " " + obj['lname'].replace(/\+/g," ");

            if(jQuery("#welcome").length > 0) {
              jQuery("#welcome").prepend("<strong>Welcome</strong> ");
              jQuery("#username").prepend('<strong>' + welcome + '</strong><span class="divider"></span>');
            } 

            // update link url
            jQuery("#loginLink a").text("Log off");
            jQuery("#loginLink a").attr("href", window.location.protocol + "//" + window.location.host + "/logoff");

            window.bmcloggedon = true;


        } else if(obj.hasOwnProperty("institution_name")) {

            // insert institution name
            welcome = obj["institution_name"].replace(/\+/g," ");
            
            if(jQuery("#welcome").length > 0) { 
                jQuery("#welcome").prepend("<strong>Welcome</strong> ");
                jQuery("#username").prepend('<strong>' + welcome + '</strong><span class="divider"></span>');
            } 

            // update link url
            jQuery("#loginLink a").text("Log on");
            jQuery("#loginLink a").attr("href", window.location.protocol + "//" + window.location.host + "/logon");

            window.bmcloggedon = false;


        } else {
            jQuery("#welcome").innerHTML = "";
            jQuery("#loginLink a").text("Log on");
            jQuery("#loginLink a").attr("href", window.location.protocol + "//" + window.location.host + "/logon");

            window.bmcloggedon = false;

        }


        // if athens login cookie doesn't exist and the athens login link is visible then remove it.
        if(allCookies.hasItem("athens") != true && document.getElementById("loginAthensLink") != null) {
          jQuery("#loginAthensLink").hide();
        }

}

login();


</script>

            <ul class="nav-sup">

    
        <li id="BMC" class="current">
            <a href="http://www.biomedcentral.com/"><span class="img-title">&nbsp;</span>
            <span class="text-title">BioMed Central</span></a>
        </li>
		
        		<li><a href="http://www.biomedcentral.com/journals"><span>Journals</span></a></li>
		
								<li>
				<a href="http://www.biomedcentral.com/gateways"><span>Gateways</span></a>
			</li>
					    	
</ul>
        </div>
    </div>
    <div class="branding-inner">

        

    
<style>
.survey {
	margin: 10px 0;
}
.survey, .survey .survey-sentence {
	font-size: 13px;
}
.survey-button a, .survey-button a:active, .survey-button a:visited, .survey-button a:hover  {
    color: #FFFFFF;
    text-decoration: none;
}
.survey-button {
	background-color: #FFA500;
    border-radius: 5px;
    color: #FFFFFF;
    font-weight: bold;
    font-size: 13px;
    font-weight: bold;
    padding: 5px 13px;
    background: #ef8142; /* Old browsers */
	background: -moz-linear-gradient(top,  #ef8142 0%, #ef8142 50%, #a64510 100%, #a64510 100%); /* FF3.6+ */
	background: -webkit-gradient(linear, left top, left bottom, color-stop(0%,#ef8142), color-stop(50%,#ef8142), color-stop(100%,#a64510), color-stop(100%,#a64510)); /* Chrome,Safari4+ */
	background: -webkit-linear-gradient(top,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* Chrome10+,Safari5.1+ */
	background: -o-linear-gradient(top,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* Opera 11.10+ */
	background: -ms-linear-gradient(top,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* IE10+ */
	background: linear-gradient(to bottom,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* W3C */
	filter: progid:DXImageTransform.Microsoft.gradient( startColorstr='#ef8142', endColorstr='#a64510',GradientType=0 ); /* IE6-9 */

}
</style>




          <div class="logo">
        <a href="/"><img alt="Trials" title="Trials Logo" src="/sites/10096/images/logo.gif" /></a>     
      </div>    
        
                    



            <div id="impact-factor" class="official">
    <img src="/images/branding/official.gif" alt="official impact factor" title="2.12"/>
    <span id="impact-factor-value">2.12</span>
</div>
    
                            

<div class="module search gray small  " role="search">
    <div class="module-inner padded">
        <form method="get" class="searchForm"
              action=" /quickSearchRedirectURL "
              onsubmit="window.location.href=this['url'].value + '?terms=' + encodeURIComponent(this['terms'].value); return false;">
            <fieldset class="search">
			                <span>
                    Search <select name="url">
                                <option value="http://www.trialsjournal.com/search/results" selected>Trials</option>
                                <option value="http://www.biomedcentral.com/search/results">BioMed Central</option>
                           </select> for
                </span>
                            <input id="searchTerms" name="terms" type="text" alt="Search terms" class="text " />
                 <button class="w37" value="Go" type="submit">Go</button>
            </fieldset>
        </form>
    </div>
	<a class="advanced-search" href="/search">Advanced search</a>
</div> 

                        <div id="mobile-nav-list" >

	<ul class="primary-nav" role="navigation">
		<li     ><a href="/"><span id="home-tab">Home</span></a></li>
														<li             class="current"
    ><a href="/content"><span id="articles-tab">Articles</span></a></li>
										
	

	
            <li     ><a href="/authors/instructions"><span id="authors-tab">Authors</span></a></li>
        <li     ><a href="/about/reviewers"><span id="reviewers-tab">Reviewers</span></a></li>
    		<li     ><a href="/about"><span id='about-tab'>About this journal</span></a></li>
	<li     ><a href="/my"><span id="my-tab">My Trials</span></a></li>
		
    		</ul>
</div>
            </div>
</div>

<hr class="hide" />
<div class="container">
	<div id="content"  class="overflow-visible"  role="main">
			    
	

<!--div class="branding-mobile">
		<h1 class="logo">
	    <a href="/">
		    <img alt="Trials" title="Trials Logo" src="/sites/10096/images/logo.gif" />
		</a>
		</h1>
	</div><br/-->



			
	



<div class="outline-wrapper block mobile-hidden" id="left-article-box">
<ul id="box-outline" class="box">
<ul id="outline" class="outline">
   <li>
      <a href="#">Top</a>
   </li>
   <li>
      <a href="#abs">Abstract</a>
   </li>
   <li>
      <a href="#sec1">Background</a>
   </li>
   <li>
      <a href="#sec2">Methods/Design</a>
   </li>
   <li>
      <a href="#sec3">Discussion</a>
   </li>
   <li>
      <a href="#sec4">Trial status</a>
   </li>
   <li>
      <a href="#sec5">Abbreviations</a>
   </li>
   <li>
      <a href="#sec6">Competing interests</a>
   </li>
   <li>
      <a href="#sec7">Authors’ contributions</a>
   </li>
   <li>
      <a href="#ack">Acknowledgements</a>
   </li>
   <li class="lowest">
      <a href="#refs">References</a>
   </li>
</ul>
</ul>

<dl id="box-outline1">
</dl>

				



</div>



<div class="mobile-hidden" id="right-panel">
 	
<div id="mobile-sidebar">
	<div id="mobile-sidebar-tab">
		<span>
			<a href="#" id="mobile-sidebar-tab-link"><img src="/images/sidebar-hidden.png"><img style="display:none;" src="/images/sidebar-shown.png"></a>
		</span>
	</div>	<div id="mobile-sidebar-list">

<div id="article-navigation-bar">
    <div class="issue-information block">
        <h5><a href="http://www.trialsjournal.com"><strong>Trials</strong></a></h5>
 		        <ul class="square normal">
            <li><a href="http://www.trialsjournal.com/content/16">Volume 16</a></li>
				
                    </ul>
    </div>

    <div class="article-information block" id="article-info">
        


<div id="viewing-options-links">
	<h5>Viewing options</h5>
	<ul class="square normal">
        
            <li>
                             <a onclick="_gaq.push(['_trackEvent', 'Abstract', 'Article Sidebar', '/content/16/1/77', 1, true]);" href="/content/16/1/77/abstract">Abstract</a>
                        </li>
        				<li>
							<strong>Full text</strong>
					</li>
				
		<li class="pdfFileSize">
			<a onclick="_gaq.push(['_trackEvent', 'PDF download', 'Article Sidebar', '/content/16/1/77', 1, true]);" href="/content/pdf/s13063-015-0602-8.pdf">PDF</a>
			<span>(594KB)</span>
		</li>

        
			</ul>

        
</div>
		
<div id="associated-material-links">
    <h5>Associated material</h5>
    <ul class="square normal">
                                    <li><a onclick="_gaq.push(['_trackEvent', 'Article metrics', 'Article Sidebar', '/content/16/1/77', 1, true]);" href="/content/16/1/77/about">Article metrics</a></li>
                <li>
                        <a onclick="_gaq.push(['_trackEvent', 'Readers comments', 'Article Sidebar', '/content/16/1/77', 1, true]);" href="/content/16/1/77/comments">Readers' comments </a>
                    </li>
        <li>
                            <a onclick="_gaq.push(['_trackEvent', 'Pre-publication history', 'Article Sidebar', '/content/16/1/77', 1, true]);" href="/content/16/1/77/prepub">Pre-publication history</a>                    </li>
    </ul>
</div>
		




<div id="related-literature-links">
    <h5>Related literature</h5>
    <ul class="normal">
                    <li><a onclick="_gaq.push(['_trackEvent', 'Citied by', 'Article Sidebar', '/content/16/1/77', 1, true]);" href="http://www.trialsjournal.com/content/16/1/77/about#citations">Cited by</a></li>
                <li id="google-blog-search"><a onclick="_gaq.push(['_trackEvent', 'Google blog search', 'Article Sidebar', '/content/16/1/77', 1, true]);" href="http://www.google.com/search?tbm=blg&hl=en&amp;source=hp&amp;biw=1280&amp;bih=899&amp;q=%22Pain+reduction+with+oral+methotrexate+in+knee+osteoarthritis%2C+a+pragmatic+phase+iii+trial+of+treatment+effectiveness+%28PROMOTE%29%3A+study+protocol+for+a+randomized+controlled+trial%22&amp;btnG=Search">Google blog search</a></li>
        <h6>Other articles by authors</h6>
        <li>
            <a class="collapser"><i>&nbsp;</i>on Google Scholar</a>
<ul id="authg" class="hidebeforeload">                         <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22SR+Kingsbury%22">Kingsbury SR</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22P+Tharmanathan%22">Tharmanathan P</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22NK+Arden%22">Arden NK</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22M+Batley%22">Batley M</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22F+Birrell%22">Birrell F</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22K+Cocks%22">Cocks K</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22M+Doherty%22">Doherty M</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22CJ+Edwards%22">Edwards CJ</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22T+Garrood%22">Garrood T</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22AJ+Grainger%22">Grainger AJ</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22M+Green%22">Green M</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22C+Hewitt%22">Hewitt C</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22R+Hughes%22">Hughes R</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22R+Moots%22">Moots R</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22TW+O’Neill%22">O’Neill TW</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22E+Roddy%22">Roddy E</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22DL+Scott%22">Scott DL</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22FE+Watt%22">Watt FE</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22DJ+Torgerson%22">Torgerson DJ</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22PG+Conaghan%22">Conaghan PG</a>
            </li>
            </ul>          </li>
                <li>
            	        </li>
    </ul>     <h6>Related articles/pages</h6>
    <ul class="square normal">
        <li><a onclick="_gaq.push(['_trackEvent', 'on google', 'Article Sidebar', '/content/16/1/77', 1, true]);" href="http://www.google.co.uk/search?hl=en&amp;q=related:http://www.trialsjournal.com/content/16/1/77">on Google</a></li>
        <li><a onclick="_gaq.push(['_trackEvent', 'on google scholar', 'Article Sidebar', '/content/16/1/77', 1, true]);" href="http://scholar.google.com/scholar?q=related:http://www.trialsjournal.com/content/16/1/77">on Google Scholar</a></li>
            </ul>

</div>		
        
    
    
        

    	






<h5>Tools</h5>
	<ul class="square normal">
									<li>
						<a onclick="_gaq.push(['_trackEvent', 'download references', 'Article Sidebar', '/content/16/1/77', 1, true]);" href="/content/16/1/77/citation">Download references</a>
					</li>
				<li><a onclick="_gaq.push(['_trackEvent', 'download xml', 'Article Sidebar', '/content/16/1/77', 1, true]);" href="/content/download/xml/s13063-015-0602-8.xml">Download XML</a></li>
				<li>
						<a onclick="_gaq.push(['_trackEvent', 'email2friend', 'Article Sidebar', '/content/16/1/77', 1, true]);" href="/content/16/1/77/email">Email to a friend</a>
					</li>
		<li><a onclick="_gaq.push(['_trackEvent', 'order reprints', 'Article Sidebar', '/content/16/1/77', 1, true]);" href="https://www.odysseypress.com/onlinehost/reprint_order.php?type=A&page=0&journal=738&doi=10.1186/s13063-015-0602-8&volume=16&issue=1&title=Pain+reduction+with+oral+methotrexate+in+knee+osteoarthritis%2C+a+pragmatic+phase+iii+trial+of+treatment+effectiveness+%28PROMOTE%29%3A+study+protocol+for+a+randomized+controlled+trial&author_name=Sarah R Kingsbury&start_page=1&end_page=14">Order reprints</a></li>
		<li>
						<a onclick="_gaq.push(['_trackEvent', 'post a comment', 'Article Sidebar', '/content/16/1/77', 1, true]);" href="/content/16/1/77/postcomment">Post a comment</a>
					</li>			
		<ul id="download-to-links">
			<a class="downloadto_title btn" href="#"><span class="icon">&nbsp;</span>Download to ...</a>
			
			<ul id="downloadto" class="iconlist hidebeforeload" style="display: none;">
				<li>
					<a href="http://redirect.papersapp.com/redirect?url=http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F77" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Papers', 'Article Sidebar', '/content/16/1/77', 1, true]);"><span class="share-icons papers"></span>Papers</a>
				</li>
				<li>
					<a href="http://www.mendeley.com/import/?url=http://www.trialsjournal.com/content/16/1/77" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Mandeley', 'Article Sidebar', '/content/16/1/77', 1, true]);"><span class="share-icons mendeley"></span>Mendeley</a>
				</li>
			</ul>
		</ul>
		
		<ul id="mobile-downloadto" class="iconlist">
		
		<h6>Download to ...</h6>
			<li>
				<a href="http://redirect.papersapp.com/redirect?url=http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F77" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Papers', 'Article Sidebar', '/content/16/1/77', 1, true]);"><span class="share-icons papers"></span>Papers</a>
			</li>
			
			<li>
				<a href="http://www.mendeley.com/import/?url=http://www.trialsjournal.com/content/16/1/77" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Mandeley', 'Article Sidebar', '/content/16/1/77', 1, true]);"><span class="share-icons mendeley"></span>Mendeley</a>
			</li>
		</ul>

		
	</ul>
		




<h5>Share this article</h5>
<ul id="social-networking-links">
	<li>
	<div class="fb-like" onclick="_gaq.push(['_trackEvent', 'Facebook Recommend', 'Article Sidebar', '/content/16/1/77', 1, true]);" data-href="http://www.trialsjournal.com/content/16/1/77" data-send="false" data-layout="button_count" data-width="100" data-show-faces="false" data-action="recommend"></div>
	</li>
	<li>
		<a onclick="_gaq.push(['_trackEvent', 'Share Twitter Recommend', 'Article Sidebar', '/content/16/1/77', 1, true]);" href="http://twitter.com/share" data-url="http://www.trialsjournal.com/content/16/1/77" data-counturl="http://www.trialsjournal.com/content/16/1/77" data-hashtags="trials
" data-text="Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial" class="twitter-share-button">Tweet</a>
	</li>
	<li>
			<g:plusone size="medium" width="100"></g:plusone>
	</li>

        <li>
        <wb:share-button onclick="_gaq.push(['_trackEvent', 'Recommend Google plus', 'Article Sidebar', '/content/16/1/77', 1, true]);" addition="number" type="button" ralateUid="2216240737" title="Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial http://www.trialsjournal.com/content/16/1/77"></wb:share-button>
    </li>
    
		<a class="sharethis_title btn" href="#"><span class="icon">&nbsp;</span>More options...</a>
	<ul class="iconlist hidebeforeload" id="sharethis">
			<li>
				<a target="_blank" onclick="_gaq.push(['_trackEvent', 'citeu Like', 'Article Sidebar', '/content/16/1/77', 1, true]);" href="http://www.citeulike.org/posturl?url=http://www.trialsjournal.com/content/16/1/77"><span class="share-icons citeulike"></span>Citeulike</a>
			</li>
				<li>
			<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share Linkedin', 'Article Sidebar', '/content/16/1/77', 1, true]);" href="http://www.linkedin.com/shareArticle?mini=true&url=%26%2335%3Btrials%0D%0APain%20reduction%20with%20oral%20methotrexate%20in%20knee%20osteoarthritis%2C%20a%20pragmatic%20phase%20iii%20trial%20of%20treatment%20effectiveness%20%28PROMOTE%29%3A%20study%20protocol%20for%20a%20randomized%20controlled%20trial%20http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F77&title=Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial"><span class="share-icons linkedin"></span>LinkedIn</a>
	</li>
			<li>
				<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share delicious', 'Article Sidebar', '/content/16/1/77', 1, true]);" href="http://del.icio.us/post?url=http://www.trialsjournal.com/content/16/1/77&title=Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial"><span class="share-icons delicious"></span>Del.icio.us</a>
	</li>
			<li>
				<a onclick="_gaq.push(['_trackEvent', 'Share via email', 'Article Sidebar', '/content/16/1/77', 1, true]);" href="/content/16/1/77/email"><span class="share-icons email"></span>Email</a>
	</li>
			<li>
				<a onclick="target="_blank" onclick="_gaq.push(['_trackEvent', 'Share facebook', 'Article Sidebar', '/content/16/1/77', 1, true]);" href="http://www.facebook.com/sharer.php?u=http://www.trialsjournal.com/content/16/1/77"><span class="share-icons facebook"></span>Facebook</a>
	</li>
	<li class="gp">
			<div class="googlehider mobile-hide"> 
				<div class="g-plusone" data-annotation="none"></div>
			</div>
				<span class="share-icons googleplus mobile-hide"></span>
				<div class="googlehider2 mobile-hide"> 
				<div class="g-plusone mobile-hide" data-annotation="none"></div>
			</div>
				<span class="share-icons googleplus"></span>
				<span class="gp-link"><a  onclick="_gaq.push(['_trackEvent', 'Share google plus', 'Article Sidebar', '/content/16/1/77', 1, true]);" href="#">Google+</a></span>
	</li>
			<li>
				<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share Mandeley', 'Article Sidebar', '/content/16/1/77', 1, true]);" href="http://www.mendeley.com/import/?url=http://www.trialsjournal.com/content/16/1/77"><span class="share-icons mendeley"></span>Mendeley</a>
			</li>
			<li>
			<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share twitter icon', 'Article Sidebar', '/content/16/1/77', 1, true]);" href="http://twitter.com/?status=Pain%20reduction%20with%20oral%20methotrexate%20in%20knee%20osteoarthritis%2C%20a%20pragmatic%20phase%20iii%20trial%20of%20treatment%20effectiveness%20%28PROMOTE%29%3A%20study%20protocol%20for%20a%20randomized%20controlled%20trial%20http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F77+%23trials
"><span class="share-icons twitter"></span>Twitter</a>
			</li>

			<li><a href="http://www.reddit.com/submit" onclick="window.location = 'http://www.reddit.com/submit?url=http://www.trialsjournal.com/content/16/1/77'; return false"> <span class="share-icons reddit"></span>Reddit</a>
    </li>






		</ul>
</ul>

    </div>

    
  
        
                
        


















                                                                                
	

	    
   
  
      
  
                  
  
                  
  
            
  
            
            

<div id="signup-to-etoc" class="button-collection-margins block mobile-border-bottom">	
					<h3>Email updates</h3>
			<p id="receive_issue_alerts_journal_updates_text">Keep up to date with the latest news and content from Trials and BioMed Central.</p>
			
				
<form  id="articleSignupForUpdates"  method="post" action="/signuptoupdates.html">
	<div id="message-box"></div>
    <fieldset class="block-form">
        <input type="text" name="emailAddress" onblur="javascript: if (this.value == '') { this.value = 'email address'; }" onfocus="javascript: if (this.value == 'email address') { this.value = ''; }" value="email address"  class="text " id="email" />
        <input value="" type="hidden" name="returnUrl" id="returnUrl" />
        <input value="xniche-trials" type="hidden" name="listName" id="listName" />
        <input value="Trials" type="hidden" name="journalName" id="journalName" />
        <button onclick="_gaq.push('_trackEvent', 'Signup', 'Signup for Email updates', "Trials");" class="w74 right" type="submit" onmouseover="this.className='w74 hover right'" onmouseout="this.className='w74 right'" value="Sign up">Sign up</button>
    </fieldset>
</form>	
</div>

	


			<div id="advert-offset">
    					
		<dl class="google-ad  ">
	<dt class="hide">
				
					<a class="skyscraper-ad" href="http://www.biomedcentral.com/advertisers/digital_advertising">Advertisement</a>
			</dt>
		<dd>

		<!-- OAS AD 'Right3' begin -->
		<script type="text/javascript">
		OAS_AD('Right3');

		</script>
		<!-- OAS AD 'Right3' end -->
		</dd>

		</dl>

		<noscript>
			<dl class="google-ad  noscript">  
    <dt class="hide"><a href="http://www.biomedcentral.com/advertisers/digital_advertising">Advertisement</dt>
    
    <dd>
        <a href="//oas.biomedcentral.com/RealMedia/ads/click_nx.ads/trialsjournal.com/article/10.1186/s13063/015/0602/8/18903129645@Right3?">
            <img src="//oas.biomedcentral.com/RealMedia/ads/adstream_nx.ads/trialsjournal.com/article/10.1186/s13063/015/0602/8/15935834207@Right3?" alt="advert"/>
        </a>
    </dd>
			</dl>
		</noscript>
					</div>
	

	
</div>
		<div class="mobile-sidebar-gradient top"></div>
		<div class="mobile-sidebar-gradient bottom"></div>
	</div>

</div>








 </div>
<div class="rounded custom white article full-text">
<div class="wrap-inner content">
    <div class="padded-inner">            


    
   
  
      
  
                  
  
                  
  
            
  
            
            

<div id="topmatter">
	


	   






 
  



				<a href="/about/access"><img alt="Open Access" src="/images/articles/openaccess-large.png" class="access mr15"/></a>
					<span class="articletype">Study protocol</span>

<h1>Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial</h1>
        
			<div class="multipleins">
		
	<p class="authors">
        																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																							         <strong>Sarah R Kingsbury</strong><sup><a href="/content/16/1/77/#ins1">1</a></sup>, <strong>Puvan Tharmanathan</strong><sup><a href="/content/16/1/77/#ins2">2</a></sup>, <strong>Nigel K Arden</strong><sup><a href="/content/16/1/77/#ins3">3</a></sup>, <strong>Michael Batley</strong><sup><a href="/content/16/1/77/#ins4">4</a></sup>, <strong>Fraser Birrell</strong><sup><a href="/content/16/1/77/#ins5">5</a></sup>, <strong>Kim Cocks</strong><sup><a href="/content/16/1/77/#ins2">2</a></sup>, <strong>Michael Doherty</strong><sup><a href="/content/16/1/77/#ins6">6</a></sup>, <strong>Chris J Edwards</strong><sup><a href="/content/16/1/77/#ins7">7</a></sup>, <strong>Toby Garrood</strong><sup><a href="/content/16/1/77/#ins8">8</a></sup>, <strong>Andrew J Grainger</strong><sup><a href="/content/16/1/77/#ins1">1</a></sup>, <strong>Michael Green</strong><sup><a href="/content/16/1/77/#ins9">9</a></sup>, <strong>Catherine Hewitt</strong><sup><a href="/content/16/1/77/#ins2">2</a></sup>, <strong>Rod Hughes</strong><sup><a href="/content/16/1/77/#ins10">10</a></sup>, <strong>Robert Moots</strong><sup><a href="/content/16/1/77/#ins11">11</a></sup>, <strong>Terence W O’Neill</strong><sup><a href="/content/16/1/77/#ins12">12</a></sup>, <strong>Edward Roddy</strong><sup><a href="/content/16/1/77/#ins13">13</a></sup>, <strong>David L Scott</strong><sup><a href="/content/16/1/77/#ins14">14</a></sup>, <strong>Fiona E Watt</strong><sup><a href="/content/16/1/77/#ins15">15</a></sup>, <strong>David J Torgerson</strong><sup><a href="/content/16/1/77/#ins2">2</a></sup> and <strong>Philip G Conaghan</strong><sup><a href="/content/16/1/77/#ins1">1</a></sup><sup>&#42;</sup>	</p>
	
				<div id="affiliations">
		<div class="module gray  inner">
<div class="module-inner padded-inner">
		<ul>
			<li>                                                                                                                                                                                                                                                            
                            		<p class="authors" >
							<span>*</span>
									 Corresponding author:										            Philip G Conaghan <a href='mailto:p.conaghan@leeds.ac.uk'>p.conaghan@leeds.ac.uk</a>    					</p>
      
</li>
			
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                		</ul>

		
		 <p class="options"><a class="affiliations-toggle" href="#"><i class="arrow"></i>Author Affiliations</a></p>            <section> 
						<div class="collapsible-content">
							
				<div id="ins_container" style="display: block;">
										    						    <p >
						        <sup id="ins1">1</sup>                                Leeds Institute of Rheumatic and Musculoskeletal Medicine and National Institute of Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Chapeltown Road, Leeds LS7 4SA, UK
                            </p>
																    						    <p >
						        <sup id="ins2">2</sup>                                York Trials Unit, Department of Health Sciences, Faculty of Science, Seebohm Rowntree Building, University of York, Heslington, York YO10 5DD, UK
                            </p>
																    						    <p >
						        <sup id="ins3">3</sup>                                NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, University of Oxford, Windmill Road, Headington, Oxford OX3 7LD, UK
                            </p>
																    						    <p >
						        <sup id="ins4">4</sup>                                Department of Rheumatology, Maidstone and Tunbridge Wells NHS Trust, Pembury, Tunbridge Wells TN2 4QJ, Kent, UK
                            </p>
																    						    <p >
						        <sup id="ins5">5</sup>                                Musculoskeletal Research Group, Institute for Cellular Medicine, Newcastle University, Musculoskeletal Research Group, 4th Floor Catherine Cookson Building, The Medical School, Framlington Place, Newcastle University, Newcastle NE2 4HH, UK
                            </p>
																    						    <p >
						        <sup id="ins6">6</sup>                                Academic Rheumatology, Clinical Sciences Building, University of Nottingham, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1 PB, UK
                            </p>
																    						    <p >
						        <sup id="ins7">7</sup>                                Department of Rheumatology and NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK
                            </p>
																    						    <p >
						        <sup id="ins8">8</sup>                                Guy’s and St Thomas’ Hospitals Foundation NHS Trust, Great Maze Pond, London SE1 9RT, UK
                            </p>
																    						    <p >
						        <sup id="ins9">9</sup>                                The York Hospital, York Hospitals NHS Foundation Trust, Wigginton Road, York YO31 8HE, UK
                            </p>
																    						    <p >
						        <sup id="ins10">10</sup>                                Rheumatology Department, St Peters Hospital, Guildford Road, Chertsey KT16 0PZ, Surrey, UK
                            </p>
																    						    <p >
						        <sup id="ins11">11</sup>                                Institute of Integrative Biology, University of Liverpool and Institute of Ageing and Chronic Disease, University Hospital Aintree, Longmoor Lane, Fazakerley, Liverpool L9 7AL, Merseyside, UK
                            </p>
																    						    <p >
						        <sup id="ins12">12</sup>                                Arthritis Research UK Centre for Epidemiology, The University of Manchester, 2nd floor, Stopford Building, Oxford Road, Manchester M13 9PT, UK
                            </p>
																    						    <p >
						        <sup id="ins13">13</sup>                                Research Institute for Primary Care and Health Sciences, Keele University, Keele ST5 5BG, Staffordshire, UK
                            </p>
																    						    <p >
						        <sup id="ins14">14</sup>                                Department of Rheumatology, King’s College London School of Medicine, King’s College London and Department of Rheumatology, King’s College Hospital, 10 Cutcombe Road, London SE5 9RJ, London, UK
                            </p>
																    						    <p >
						        <sup id="ins15">15</sup>                                Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road, Oxford, OX3 7HE, UK and Imperial College London, South Kensington Campus, London SW7 2AZ, UK
                            </p>
																
				</div>
										<p id="authoremails">            For all author emails, please <a href="/logon">log on</a>.
    </p>
						</div>
			</section>
				</div>
</div>
		</div>
	  </div>

            <section class="cit">
                        <div class="collapsible-content">
        <p><em>Trials</em> 2015, <strong>16</strong>:77&nbsp;
			<span class="pseudotab">doi:10.1186/s13063-015-0602-8</span></p>
	    				    
    
        
                
		<p>The electronic version of this article is the complete one and can be found online at: <a href="http://www.trialsjournal.com/content/16/1/77">http://www.trialsjournal.com/content/16/1/77</a></p>
		<br/>
                    <table cellspacing="0" cellpadding="0">
        <tbody>
        <tr><td>Received:</td><td>5 November 2014</td></tr>                <tr><td>Accepted:</td><td>11 February 2015</td></tr>        <tr><td>Published:</td><td>4 March 2015</td></tr>        </tbody>
        </table>
    		<!--<br/>-->
		<div  style="line-height:140%">
        <p>
            &copy; 2015 Kingsbury et al.; licensee BioMed Central. <br />
        </p>
					<p>
				This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<a href='http://creativecommons.org/licenses/by/4.0'>http://creativecommons.org/licenses/by/4.0</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
			</p>
		    	</div>
	</section>

</div>
<div id="article-body">
    <section><a name="abs"></a><h3>Abstract</h3>
   <div class="collapsible-content">
      <h4>Background</h4>
      <p style="line-height:160%">Osteoarthritis (OA) is the fastest growing cause of disability worldwide. Current
         treatments for OA are severely limited and a large proportion of people with OA live
         in constant, debilitating pain. There is therefore an urgent need for novel treatments
         to reduce pain. Synovitis is highly prevalent in OA and is associated with pain. In
         inflammatory arthritides such as rheumatoid arthritis, methotrexate (MTX) is the gold
         standard treatment for synovitis and has a well-known, acceptable toxicity profile.
         We propose that using MTX to treat patients with symptomatic knee OA will be a practical
         and safe treatment to reduce synovitis and, consequently, pain.
      </p>
      <h4>Methods/Design</h4>
      <p style="line-height:160%">Pain Reduction with Oral Methotrexate in knee Osteoarthritis, a pragmatic phase III
         trial of Treatment Effectiveness (PROMOTE) is an investigator-initiated, multi-centre,
         randomized, double-blind, pragmatic placebo-controlled trial. A total of 160 participants
         with symptomatic knee OA will be recruited across primary and secondary care sites
         in the United Kingdom and randomized on a 1:1 basis to active treatment or placebo,
         in addition to usual care, for 12&nbsp;months. As is usual practice for MTX, dosing will
         be escalated over six weeks to 25&nbsp;mg (or maximum tolerated dose) weekly for the remainder
         of the study. The primary endpoint is change in average knee pain during the past
         week (measured on an 11-point numerical rating scale) between baseline and six months.
         Secondary endpoints include other self-reported pain, function and quality-of-life
         measures. A health economics analysis will also be performed. A magnetic resonance
         imaging substudy will be conducted to provide an explanatory mechanism for associated
         symptom change by examining whether MTX reduces synovitis and whether this is related
         to symptom change. Linear and logistic regression will be used to compare changes
         between groups using univariable and multivariable modelling analyses. All analyses
         will be conducted on an intention-to-treat basis.
      </p>
      <h4>Discussion</h4>
      <p style="line-height:160%">The PROMOTE trial is designed to examine whether MTX is an effective analgesic treatment
         for OA. The MRI substudy will address the relationship between synovitis and symptom
         change. This will potentially provide a much needed new treatment for knee OA.
      </p>
      <h4>Trial registration</h4>
      <p style="line-height:160%">Current Controlled Trials identifier: <a href="ISRCTN77854383">ISRCTN77854383</a> <a href="http://www.webcitation.org/query.php?url=ISRCTN77854383&amp;refdoi=10.1186/s13063-015-0602-8" alt="" title="Archive copy of webpage" class="xpushbutton">webcite</a> (registered: 25 October 2013).
      </p>
   </div>
</section><span id="keywords">
   <h5 class="inline">Keywords: </h5>Double-blind; Knee osteoarthritis; Methotrexate; Placebo-controlled; Randomized</span><section><a name="sec1"></a><h3>Background</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">With a rapidly ageing population, osteoarthritis (OA) has become the fastest growing
         cause of disability worldwide <a name="d3712e347"></a>[<a onclick="LoadInParent('#B1'); return false;" href="#B1">1</a>],<a name="d3712e351"></a>[<a onclick="LoadInParent('#B2'); return false;" href="#B2">2</a>]. Current estimates suggest that over 250 million people across the globe are affected
         by OA, with a lifetime risk for the development of knee OA of approximately 40% <a name="d3712e355"></a>[<a onclick="LoadInParent('#B1'); return false;" href="#B1">1</a>]-<a name="d3712e359"></a>[<a onclick="LoadInParent('#B3'); return false;" href="#B3">3</a>]. OA is characterized by chronic joint pain and functional impairment, resulting in
         markedly reduced quality of life for individuals. OA also places an enormous burden
         on health services and health economies, and is the second leading cause of absence
         from work <a name="d3712e363"></a>[<a onclick="LoadInParent('#B4'); return false;" href="#B4">4</a>]. The cumulative cost of OA has been estimated to amount to approximately 1% of gross
         national product <a name="d3712e368"></a>[<a onclick="LoadInParent('#B5'); return false;" href="#B5">5</a>],<a name="d3712e372"></a>[<a onclick="LoadInParent('#B6'); return false;" href="#B6">6</a>].
      </p>
      <p style="line-height:160%">One of the major barriers to reducing the impact of OA, both on individuals and society,
         is the lack of efficacious therapies available to treat the symptoms of OA or to slow
         the disease process and associated structural progression. Current management guidelines
         for OA include pharmacological therapies such as paracetamol and NSAIDs, and non-pharmacological
         therapies including weight loss and exercise <a name="d3712e378"></a>[<a onclick="LoadInParent('#B7'); return false;" href="#B7">7</a>]-<a name="d3712e382"></a>[<a onclick="LoadInParent('#B9'); return false;" href="#B9">9</a>]. Although current treatments are aimed at providing symptomatic relief, recent studies
         suggest that the large majority of people with OA live in constant pain despite use
         of available therapies <a name="d3712e386"></a>[<a onclick="LoadInParent('#B10'); return false;" href="#B10">10</a>]. These therapies are also associated with significant toxicities. In addition, because
         the typical OA patient is of advanced age with multiple comorbidities, many have contraindications
         to the use of traditional OA medications. Hence, there is a pressing need to identify
         alternative therapies for OA in order to tackle this increasing problem <a name="d3712e390"></a>[<a onclick="LoadInParent('#B11'); return false;" href="#B11">11</a>],<a name="d3712e394"></a>[<a onclick="LoadInParent('#B12'); return false;" href="#B12">12</a>].
      </p>
      <p style="line-height:160%">There is increasing evidence, particularly from imaging studies, of a high prevalence
         of synovitis (inflammation of the synovial membrane) in OA, with abnormalities present
         from the earliest stages of the disease and associated with the presence and severity
         of pain <a name="d3712e400"></a>[<a onclick="LoadInParent('#B13'); return false;" href="#B13">13</a>]-<a name="d3712e404"></a>[<a onclick="LoadInParent('#B18'); return false;" href="#B18">18</a>]. These changes are often indistinguishable to those observed in rheumatoid arthritis
         (RA), although they are generally confined to more discrete regions within the joint,
         generally adjacent to sites of chondropathy. Increased levels of pro-inflammatory
         cytokines (such as tumour necrosis factor (TNF)α, interleukin (IL)-1β and IL-6), reduced
         levels of anti-inflammatory cytokines (such as IL-10 and IL-1RA), infiltration of
         mononuclear cells and adaptive immune cell responses have all been demonstrated within
         OA fluid and tissue, suggesting that modulating the inflammatory response may be effective
         as a treatment target for OA <a name="d3712e408"></a>[<a onclick="LoadInParent('#B19'); return false;" href="#B19">19</a>]-<a name="d3712e412"></a>[<a onclick="LoadInParent('#B21'); return false;" href="#B21">21</a>].
      </p>
      <p style="line-height:160%">The rationale for targeting synovitis as a treatment for OA pain is supported by previous
         studies of anti-inflammatory agents. Randomized controlled trials of non-steroidal
         anti-inflammatory drugs (NSAIDs) and the fewer randomized controlled trials of intra-articular
         (IA) and oral corticosteroids have demonstrated modest, short-term pain reduction
         associated with anti-inflammatory effects and reduced synovitis <a name="d3712e418"></a>[<a onclick="LoadInParent('#B22'); return false;" href="#B22">22</a>]-<a name="d3712e422"></a>[<a onclick="LoadInParent('#B27'); return false;" href="#B27">27</a>]. However, although NSAIDs and corticosteroids have positive short-term effects their
         long-term use is not desirable, with contra-indications to their use in many people
         with OA.
      </p>
      <p style="line-height:160%">Disease modifying anti-rheumatic drugs (DMARDs) are the mainstay of treatment for
         RA and all have anti-synovial effects. Methotrexate ((MTX) 4-amino-10-methylfolic
         acid) is the first-line treatment widely used to treat synovitis in the inflammatory
         arthritides, and current evidence suggests it is the most effective DMARD and safe
         for long-term use <a name="d3712e428"></a>[<a onclick="LoadInParent('#B28'); return false;" href="#B28">28</a>]. Indications for the use of MTX have expanded in recent years to include trials to
         reduce cardiovascular disease (CVD) in the general population, as well as showing
         reductions in CVD in RA patients <a name="d3712e432"></a>[<a onclick="LoadInParent('#B29'); return false;" href="#B29">29</a>]. There is more uncertainty about the benefits of MTX in other peripheral joint arthritides
         such as psoriatic arthritis (PsA), however this may reflect a lack of robust trial
         data <a name="d3712e436"></a>[<a onclick="LoadInParent('#B30'); return false;" href="#B30">30</a>].
      </p>
      <p style="line-height:160%">MTX is a folic acid antagonist which has both an anti-proliferative and an anti-inflammatory
         action. The anti-proliferative activity of MTX is mediated through inhibition of the
         <em>de novo</em> synthesis of purines and pyrimidines by acting as a specific antagonist of folic
         acid. MTX was initially used in high doses for its anti-proliferative effect in the
         treatment of cancer, at doses of up to 5,000&nbsp;mg per week. At much lower doses (15
         to 25&nbsp;mg per week), as used in inflammatory arthritis, MTX has an anti-inflammatory
         effect by inducing an increase in adenosine release from cells through selective inhibition
         of aminoimidazole carboxamide ribonucleotide (AICAR) transformylase, an enzyme that
         catalyses an intermediary step in <em>de novo</em> purine biosynthesis. Extracellular adenosine is a potent inhibitor of inflammation,
         suppressing the inflammatory functions of neutrophils, macrophages and monocytes,
         dendritic cells and lymphocytes, thereby reducing secretion of inflammatory cytokines,
         including TNFα and IL-6, which drive synovitis <a name="d3712e448"></a>[<a onclick="LoadInParent('#B31'); return false;" href="#B31">31</a>],<a name="d3712e452"></a>[<a onclick="LoadInParent('#B32'); return false;" href="#B32">32</a>].
      </p>
      <p style="line-height:160%">Given the high levels of pro-inflammatory cytokines and the evidence of immune cell
         infiltration into OA joints, coupled with the strong correlations observed between
         synovitis and pain, there is rationale for the use of MTX for reducing symptoms in
         OA. Most patients tolerate MTX for long-term use <a name="d3712e458"></a>[<a onclick="LoadInParent('#B33'); return false;" href="#B33">33</a>] and the use of folic acid concomitantly with MTX reduces the incidence of side-effects
         <a name="d3712e462"></a>[<a onclick="LoadInParent('#B34'); return false;" href="#B34">34</a>]. Patients undergo regular blood monitoring to assess for toxicity, and abnormalities
         in results usually respond to a dose reduction or temporary cessation, or an increase
         in folic acid supplementation. Side-effects of MTX can include gastrointestinal side-effects,
         haematological abnormalities and elevated liver transaminases. Side-effects resulting
         in discontinuation of the drug vary in frequency from 15 to 17% <a name="d3712e466"></a>[<a onclick="LoadInParent('#B35'); return false;" href="#B35">35</a>],<a name="d3712e470"></a>[<a onclick="LoadInParent('#B36'); return false;" href="#B36">36</a>], but have been shown to reduce to 4% in the second year of treatment <a name="d3712e474"></a>[<a onclick="LoadInParent('#B35'); return false;" href="#B35">35</a>].
      </p>
      <p style="line-height:160%">To date there have been no large trials of MTX for treating OA. Two small studies,
         one in knee OA and the other in hand OA, have been carried out and these had conflicting
         results (Figure&nbsp;<a name="d3712e479"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/77/figure/F1','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/77/figure/F1">1</a> and Table&nbsp;<a name="d3712e482"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/77/table/T1','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/77/table/T1">1</a>) <a name="d3712e486"></a>[<a onclick="LoadInParent('#B37'); return false;" href="#B37">37</a>],<a name="d3712e490"></a>[<a onclick="LoadInParent('#B38'); return false;" href="#B38">38</a>]. One additional study examined the effect of MTX in calcium pyrophosphate crystal
         disease (CPPD) <a name="d3712e494"></a>[<a onclick="LoadInParent('#B39'); return false;" href="#B39">39</a>]. However, these studies included very low patient numbers and small doses of MTX,
         which makes it difficult to determine whether the results are valid.
         
         
      </p><div class="figs">
      <div class="fig"><p><a onclick="popup('http://www.trialsjournal.com/content/16/1/77/figure/F1','F1',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/77/figure/F1"><img align="top" src="/content/figures/s13063-015-0602-8-1.gif" alt="thumbnail" class="thumbnail"><strong>Figure 1.</strong></a> <strong>Overview of systematic review of methotrexate use in osteoarthritis.</strong> Databases: PubMed, MEDLINE and Embase. Search terms: MeSH headings #1 ‘osteoarthritis’
         and #2 ‘methotrexate’. Limits: Humans.
      </div>
      <div class="table"><p><a onclick="popup('http://www.trialsjournal.com/content/16/1/77/table/T1','T1',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/77/table/T1"><strong>Table 1.</strong></a> <strong>Systematic review of methotrexate use in osteoarthritis</strong></div></div>
      <p style="line-height:160%">More recently, we conducted an open-label pilot study of 30 patients with knee OA
         who took MTX for six months <a name="d3712e626"></a>[<a onclick="LoadInParent('#B40'); return false;" href="#B40">40</a>]. A total of 23 patients completed the study, 20 of whom were taking a MTX dose of
         15&nbsp;mg/week or more. At six months, 50% of patients had a 20% reduction in pain, whilst
         37% had a 40% reduction in pain. Of the seven participants who did not complete the
         study, four withdrew due to side effects (lethargy, nausea and headaches in three
         patients and thrush in one patient) and three withdrew due to lack of response. Further
         evidence for the potential of MTX as a therapy for OA can be extrapolated from animal
         studies, with positive effects on cartilage demonstrated in lapine models of OA <a name="d3712e630"></a>[<a onclick="LoadInParent('#B41'); return false;" href="#B41">41</a>],<a name="d3712e634"></a>[<a onclick="LoadInParent('#B42'); return false;" href="#B42">42</a>].
      </p>
      <p style="line-height:160%">Taken together these clinical and experimental studies suggest potential for MTX as
         a useful treatment for OA. We propose that treating patients with symptomatic knee
         OA with MTX will be a practical and safe treatment to reduce synovitis and therefore
         reduce pain. We believe that the preliminary data from the handful of small studies
         previously conducted, including our pilot study, strongly support the need for a well-designed,
         adequately powered, randomized placebo-controlled trial to examine fully the potential
         use of MTX as a treatment for OA. The Pain Reduction with Oral Methotrexate in knee
         Osteoarthritis, a pragmatic phase III trial of Treatment Effectiveness (PROMOTE) was
         designed to this end.
      </p>
      <p style="line-height:160%">This paper states the objective of the PROMOTE trial, discusses study design challenges
         encountered in its planning, and outlines the resultant study design and protocol
         for the PROMOTE trial.
      </p>
      <h4>Trial objectives</h4>
      <p style="line-height:160%">The primary objective of the trial is to determine whether MTX reduces pain associated
         with knee OA as compared to placebo. Secondary objectives of the trial are:
      </p>
      <p style="line-height:160%">1. To determine whether MTX improves function,</p>
      <p style="line-height:160%">2. To determine whether MTX improves quality of life and</p>
      <p style="line-height:160%">3. To determine whether MTX is a cost-effective treatment for knee OA.</p>
      <p style="line-height:160%">In addition to the main study, PROMOTE contains a magnetic resonance imaging (MRI)
         substudy and a biological substudy. Patients enrolled in the main study may opt to
         enrol in one, both or neither of the sub-studies. The objective of the MRI substudy
         is to provide an explanatory mechanism for associated symptom change by examining
         whether MTX reduces synovitis, and whether this is related to symptom change. The
         objective of the biological substudy is to determine whether baseline soluble immunological
         and inflammatory biomarkers predict response to treatment, and whether changes in
         levels occur following treatment with MTX.
      </p>
      <h4>Trial development</h4>
      <p style="line-height:160%">The trial was designed with key stakeholders including rheumatologists with experience
         of treating OA, general practitioners with a special interest in musculoskeletal disease,
         methodologists and users with experience of knee OA. The intention was to be pragmatic,
         allowing physicians to include MTX in the overall care of patients with knee OA and
         have relative flexibility in this regard, thereby being representative of clinical
         practice. We faced a number of challenges in achieving the ideal design for the PROMOTE
         trial which are discussed in more detail in the relevant sections below. Key challenges
         included defining the dosing and dose escalation strategy for use of MTX in OA patients,
         maintaining the blind due to the well-known side-effect profile of MTX, timing of
         the primary outcome, ensuring optimal recruitment for a trial that is conducted in
         secondary care for a condition where patients predominantly reside in primary care
         and maintaining the pragmatic nature of the trial with respect to concomitant medication
         use, whilst protecting the validity of the primary pain outcome.
      </p>
   </div>
</section>
<section><a name="sec2"></a><h3>Methods/Design</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">The PROMOTE trial is an investigator-initiated, multi-centre, 160 patient, randomized
         placebo-controlled trial to compare the reduction in pain associated with knee OA
         with MTX as compared to placebo. Participants will be randomized on a 1:1 basis to
         MTX or placebo, and treatment will be for 12&nbsp;months.
      </p>
      <h4>Population</h4>
      <p style="line-height:160%">All adults with symptomatic radiographic knee OA and inadequate response or toxicity
         to their existing medication (to include paracetamol, NSAIDs or opioid).
      </p>
      <h4>Intervention and comparator</h4>
      <p style="line-height:160%">Participants will be randomized to receive either over-encapsulated MTX 2.5&nbsp;mg tablets
         (packed with microcrystalline cellulose (Sharp Clinical Services (UK) Ltd, Crickhowell,
         Wales)) or placebo (matching capsules packed with microcrystalline cellulose (Sharp
         Clinical Services (UK) Ltd, Crickhowell, Wales)).
      </p>
      <h4>Choice of dosing for methotrexate in patients with osteoarthritis</h4>
      <p style="line-height:160%">MTX is currently used in RA with a maximum dose of 25&nbsp;mg per week. Previous small
         studies in OA have used lower doses than those used in RA <a name="d3712e686"></a>[<a onclick="LoadInParent('#B37'); return false;" href="#B37">37</a>],<a name="d3712e690"></a>[<a onclick="LoadInParent('#B38'); return false;" href="#B38">38</a>]; however to alleviate concerns around inefficacy due to inadequate dosing, we will
         follow current guidelines for use of MTX in RA as the model for the PROMOTE trial.
         Participants will be prescribed 10&nbsp;mg MTX or placebo weekly for two weeks, followed
         by 15&nbsp;mg weekly for two weeks, 20&nbsp;mg weekly for two weeks and 25&nbsp;mg weekly for the
         remainder of the study if there is no toxicity as determined at the physician’s discretion
         <a name="d3712e694"></a>[<a onclick="LoadInParent('#B43'); return false;" href="#B43">43</a>],<a name="d3712e698"></a>[<a onclick="LoadInParent('#B44'); return false;" href="#B44">44</a>]. In practice, slower dose escalation may be necessary in some participants, and deviations
         from this protocol (for example escalation by 2.5&nbsp;mg every two weeks) will be permitted
         at the clinician’s discretion to bring participants to the maximum tolerated dose
         as closely in line with the stated strategy as possible.
      </p>
      <p style="line-height:160%">If participants show toxicity to MTX upon dose escalation the dose will be dropped
         to the maximum tolerated dose (minimum dose, 7.5&nbsp;mg/week) and this will be maintained
         for the duration of the study. In our pilot study of MTX in OA, 20 of the 23 participants
         completing the study did so on a dose of 15&nbsp;mg or more. Dose reduction (to 7.5 to
         12.5&nbsp;mg) was required in four participants; one due to renal impairment and three
         due to side effects (nausea, headache and sore roof of mouth), all of which improved
         upon dose reduction. Participants who are intolerant of oral MTX will not be switched
         to subcutaneous MTX (a common practice for RA), due to complexities in maintaining
         the blind.
      </p>
      <p style="line-height:160%">All participants will be routinely reminded and encouraged to comply with the prescribed
         dose of investigational medicinal product (IMP). However, given the long half-life
         of MTX, those who miss doses of IMP will be allowed to restart medication if they
         so wish, and will not be handled differently during the course of follow-up. For the
         purposes of analysis, a participant missing more than four doses of MTX within any
         three-month period will be counted as a ‘non-complier’.
      </p>
      <h4>Non-investigational medicinal product</h4>
      <p style="line-height:160%">All participants will be prescribed oral folic acid 5&nbsp;mg tablets to be taken on the
         six consecutive days after taking the weekly MTX or placebo dose. Folic acid supplementation
         has been shown to ameliorate side effects associated with MTX’s activity as an antagonist
         of folic acid metabolism <a name="d3712e712"></a>[<a onclick="LoadInParent('#B45'); return false;" href="#B45">45</a>].
      </p>
      <h4>Concomitant medication</h4>
      <p style="line-height:160%">In order to maintain the pragmatic nature of the trial, there are no restrictions
         written into the protocol with regard to concomitant analgesic medications. All participants,
         whether on MTX or placebo, will be allowed to continue taking the treatments for knee
         OA that they are taking at their screening visit for the duration of the trial. Investigators
         will be responsible for the overall management of a participant’s medication, and
         will ask participants to avoid changing their analgesic or anti-inflammatory medication
         for the duration of the trial. However, if a participant is experiencing increased
         pain and requires an increase in the dose of analgesics then the use of paracetamol,
         topical or oral NSAIDs or opioids, or a combination of these will be permitted, but
         the reason for the dose increase and the dose used will be documented. The choice
         of medications and doses to be used lie with the principal investigator and clinicians
         working at study sites in order to ensure that treatment for participants in both
         groups is optimized. Participants will be permitted to continue current use of chondroitin
         and glucosamine, provided the dose has been stable for three months at study entry;
         however their use must be clearly documented in the case report form (CRFChondroitin
         or glucosamine therapy will not be commenced during the duration of the trial. Chronic
         NSAID and opioid use days in the last three months) will be included as a covariate
         in the analysis.
      </p>
      <p style="line-height:160%">The exception to this rule is corticosteroid use, since corticosteroids may have a
         significant effect on a participant’s experience of pain, to the point of affecting
         response to the primary outcome. Whilst there will be no overall restriction on the
         use of corticosteroids, the protocol provides guidance to investigators on the use
         of corticosteroids in order to minimise effects on the primary outcome, as detailed
         below. Participants will be asked not to use corticosteroids (oral, intravenous, IA
         or intra-muscular) between months three to six of the trial (three months before the
         primary endpoint). In months zero to three and six to 12 a single IA corticosteroid
         (in a non-knee joint) and up to one week of oral corticosteroids will be permitted.
         If corticosteroids are deemed necessary for medical reasons then their date of use,
         dose, route and indication must be clearly documented in the CRF. Patients will be
         offered the option of a rescue IA corticosteroid injection to their signal knee after
         the six-month visit of the trial if their symptoms are intolerable despite current
         medication. Corticosteroid use is ultimately at the discretion of the principal investigatoror
         study physician. All steroid use must be notified to the PROMOTE trial team centrally,
         but this will not affect the participant’s continued follow-up in the trial.
      </p>
      <h4>Outcome measures</h4>
      <p style="line-height:160%">The PROMOTE trial will examine a range of clinical, imaging and quality-of-life and
         economic outcomes, in line with the objectives listed.
      </p>
      <h4>Clinical outcome measures</h4>
      <p style="line-height:160%">The primary endpoint of the study will be change in ‘average overall knee pain severity
         over the previous week’ (as graded on a zero to 10 numerical rating scale (NRS)) between
         baseline and six months (24&nbsp;weeks). An NRS was chosen to measure pain as they have
         been found to be reliable and to demonstrate good face and criterion validity, and
         they are recommended as a core outcome measure for chronic pain clinical trials by
         the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT)
         <a name="d3712e736"></a>[<a onclick="LoadInParent('#B46'); return false;" href="#B46">46</a>]-<a name="d3712e740"></a>[<a onclick="LoadInParent('#B50'); return false;" href="#B50">50</a>].
      </p>
      <p style="line-height:160%">The timing of the primary outcome at six months was defined due to the slow-acting
         nature of MTX. Studies in RA have found that several months of treatment may be required
         before any symptomatic effect is noted <a name="d3712e746"></a>[<a onclick="LoadInParent('#B43'); return false;" href="#B43">43</a>],<a name="d3712e750"></a>[<a onclick="LoadInParent('#B44'); return false;" href="#B44">44</a>]. Our own recent study of MTX versus MTX plus etanercept in RA, in which the MTX arm
         used the same dosing schedule as that planned for the PROMOTE trial, found that approximately
         20% of participants in the MTX arm showed a major clinically significant response
         (tender and swollen joint count of zero) at three months, with this rising to 29%
         at six months and 33% at 12&nbsp;months. In our pilot study of MTX in OA, the reduction
         in 48-hour pain VAS scores was significantly greater at 24&nbsp;weeks (median (interquartile
         range (IQR)) reduction of 27&nbsp;mm (four to 38)) than at 12&nbsp;weeks (median (IQR) reduction
         of 9&nbsp;mm (−1 to 36)).The dose escalation schedule for the PROMOTE trial requires a
         minimum of six weeks to reach maximum dosage, and in reality we know that it can often
         take longer than this to escalate the dosage. Taken together with evidence from the
         RA literature, which suggests that at least two to three months may be required at
         maximal dose for symptomatic benefit to be achieved, a primary outcome earlier than
         six months may fail to fully capture the clinical response to treatment. However,
         additional outcomes will be recorded at three months (12&nbsp;weeks) to identify early
         response, and nine and 12&nbsp;months (36 and 48&nbsp;weeks) to capture longevity of response.
      </p>
      <p style="line-height:160%">Secondary outcome measures include self-reported assessment of pain and function using
         11-point NRSs to assess worst knee pain severity, global disease activity and satisfaction
         with knee function over the past week, together with the pain, function and stiffness
         subscales of the Western Ontario McMaster Universities Index (WOMAC version 3.1) and
         the Intermittent and Constant Osteoarthritis Pain scale (ICOAP). Depression and anxiety
         will be assessed using the Hospital Anxiety and Depression Scale (HADS). These measures
         are outlined further in Table&nbsp;<a name="d3712e755"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/77/table/T2','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/77/table/T2">2</a>.
         
      </p><div class="figs">
      <div class="table"><p><a onclick="popup('http://www.trialsjournal.com/content/16/1/77/table/T2','T2',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/77/table/T2"><strong>Table 2.</strong></a> <strong>Outcome measures</strong></div></div>
      <h4>Quality-of-life and health economic outcome measures</h4>
      <p style="line-height:160%">Utility will be measured using the EuroQol (EQ-5D-5&nbsp;L), deriving quality-adjusted
         life years (QALYs) for each participant. Disease-specific quality-of-life measures
         are listed in Table&nbsp;<a name="d3712e1190"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/77/table/T2','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/77/table/T2">2</a>.
      </p>
      <h4>Imaging outcome measures</h4>
      <p style="line-height:160%">Gadolinium-enhanced 1.5/3.0&nbsp;T MRI of the signal knee will be performed at baseline
         and six months according to the protocol outlined in Table&nbsp;<a name="d3712e1199"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/77/table/T3','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/77/table/T3">3</a>. All images will be quality controlled by an experienced musculoskeletal radiologist
         within two weeks of acquisition to ensure that the image quality is sufficient for
         scoring purposes. MRIs will be centrally scored semi-quantitatively and quantitatively
         at the end of the study. Semi-quantitative scoring will be conducted using the MRI
         Osteoarthritis Knee Score (MOAKS) <a name="d3712e1203"></a>[<a onclick="LoadInParent('#B51'); return false;" href="#B51">51</a>]. Images will be quantitatively scored using statistical shape modelling technology
         to automatically quantitate total and compartmental synovial volume, total and compartmental
         bone shape and other relevant features including cartilage morphology <a name="d3712e1207"></a>[<a onclick="LoadInParent('#B52'); return false;" href="#B52">52</a>].
         
      </p><div class="figs">
      <div class="table"><p><a onclick="popup('http://www.trialsjournal.com/content/16/1/77/table/T3','T3',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/77/table/T3"><strong>Table 3.</strong></a> <strong>Magnetic resonance imaging acquisition protocol</strong></div></div>
      <h4>Sample size</h4>
      <p style="line-height:160%">The standard deviation used in the sample size calculation is an estimate from previous
         studies. The internal pilot study will be used to re-estimate the sample size required
         and increase the recruitment target if necessary.
      </p>
      <p style="line-height:160%">A data-driven analysis which related change on an NRS with patient global assessment
         of change using data from 10 similar trials of chronic pain showed that a 30% change,
         or two points on the NRS was related to change of clinical importance in chronic pain.
         The correlation between clinician and patient global assessment of change was high
         in this review, and the large sample size used underscores the external validity of
         these estimates <a name="d3712e1320"></a>[<a onclick="LoadInParent('#B53'); return false;" href="#B53">53</a>]. This estimate of a two-point change on a NRS being associated with a ‘much better’
         improvement was also seen in a prospective cohort of patients with chronic musculoskeletal
         pain <a name="d3712e1324"></a>[<a onclick="LoadInParent('#B54'); return false;" href="#B54">54</a>].
      </p>
      <p style="line-height:160%">In a recent placebo-controlled, 121 patient, OA knee trial using an 11-point pain
         NRS as the primary outcome, the mean (standard deviation (SD)) baseline pain score
         was 6.1 (2.1) in the control group, 7.7 (1.4) in the placebo group, 7.1 (2.8) in treatment
         group A and 6.7 (2.5) in treatment group B <a name="d3712e1330"></a>[<a onclick="LoadInParent('#B55'); return false;" href="#B55">55</a>]. In a separate 73 patient OA knee trial, the mean (SD) baseline pain score was 4.0
         (2.1) in group A and 4.3 (1.9) in group B. At 12&nbsp;months, the mean (SD) within-group
         difference was 0.9 (2.1) for group A and 1.3 (2.4) for group B <a name="d3712e1334"></a>[<a onclick="LoadInParent('#B56'); return false;" href="#B56">56</a>]. For the sample size calculation an SD of 4 is used as a conservative estimate.
      </p>
      <p style="line-height:160%">The expected consistency in baseline pain among our trial population allows the use
         of raw change in score, rather than percentage change <a name="d3712e1340"></a>[<a onclick="LoadInParent('#B53'); return false;" href="#B53">53</a>]. In order to detect a two-point change, with an assumed SD of 4 (80% power and 5%
         significance level), 64 participants per arm are required. Allowing for a conservative
         20% dropout rate, a total of 160 participants will therefore need to be recruited
         into the study.
      </p>
      <h4>Trial procedures</h4>
      <p style="line-height:160%">Ethical approval for the study has been granted by the Leeds West Research Ethics
         Committee (reference number 13/YH/0279). Informed written consent will be obtained
         from all participants.
      </p>
      <h4>Participant recruitment strategy</h4>
      <p style="line-height:160%">Since knee OA is primarily managed within primary care, our recruitment strategy must
         enable a clear interface between primary care centres and the secondary care sites
         at which trial activity will take place. Relevant Clinical Commissioning Group (CCG)
         approvals will be obtained to enable primary care sites to act as Patient Identification
         Centres (PICs), with potentially eligible patients referred on to local secondary
         care study teams.
      </p>
      <p style="line-height:160%">A total of 160 subjects with symptomatic knee OA will be recruited and randomly allocated
         to either the treatment or placebo control group. Recruitment methods will include
         advertisements through the local media and community groups, invitations to previous
         study participants who have given their consent to be contacted regarding future research
         projects and liaisons with musculoskeletal physicians, general practitioners and allied
         health professionals. Recruitment will be initiated at all sites as soon as local
         approvals are in place, therefore recruitment to the pilot phase may occur from multiple
         sites. There will be no pause in recruitment once 30 patients are recruited, as the
         outcome from the analysis of the pilot phase will be to either continue to the planned
         numbers or to increase the planned sample size.
      </p>
      <h4>Informed consent and participant confidentiality</h4>
      <p style="line-height:160%">Informed consent will be obtained before patients are screened for participation in
         the PROMOTE trial. The right of the patient to refuse consent without giving reasons
         will be respected. Further, the patient will remain free to withdraw from the study
         at any time without giving reasons and without prejudicing any further treatment.
         The written consent will be obtained by an appropriately delegated clinician who is,
         by education and experience, qualified to do so, and who has signed and dated the
         staff authorization and delegation log. The process of obtaining written consent will
         be clearly documented in the patient’s medical notes. Patient confidentiality will
         be guaranteed at all times, in line with the requirements of the United Kingdom Data
         Protection Act 1998 and NHS regulations.
      </p>
      <h4>Eligibility criteria</h4>
      <p style="line-height:160%">Participants must meet the inclusion and exclusion criteria (shown in Table&nbsp;<a name="d3712e1369"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/77/table/T4','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/77/table/T4">4</a>) in order to participate. These will be assessed at the screening visit (Figure&nbsp;<a name="d3712e1372"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/77/figure/F2','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/77/figure/F2">2</a>). Potential participants who are deemed ineligible at screening will be allowed a
         second screening visit if the reason for ineligibility is a temporary status (for
         example, recent corticosteroid injection; Table&nbsp;<a name="d3712e1375"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/77/table/T4','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/77/table/T4">4</a>).
         
         
      </p><div class="figs">
      <div class="table"><p><a onclick="popup('http://www.trialsjournal.com/content/16/1/77/table/T4','T4',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/77/table/T4"><strong>Table 4.</strong></a> <strong>Eligibility criteria</strong></div>
      <div class="fig"><p><a onclick="popup('http://www.trialsjournal.com/content/16/1/77/figure/F2','F2',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/77/figure/F2"><img align="top" src="/content/figures/s13063-015-0602-8-2.gif" alt="thumbnail" class="thumbnail"><strong>Figure 2.</strong></a> <strong>Participant flowchart.</strong> EQ-5D, EuroQol 5D-5&nbsp;L; HADS, hospital anxiety and depression scale; ICOAP, intermittent
         and constant osteoarthritis pain scale; MRI, magnetic resonance imaging; MTX, methotrexate;
         NHS, National Health Service; NRS, numerical rating scale; OA QoL, osteoarthritis
         quality of life; PIS, patient information sheet; SF-12, Short Form-12; WOMAC, Western
         Ontario and McMaster Osteoarthritis Index. Treatment assignment and allocation concealment.
      </div></div>
      <p style="line-height:160%">Identical over-encapsulated MTX and placebo capsules will be produced to ensure allocation
         concealment. Upon production, study medication will be packed into bulk numbered bottles
         according to a randomization schedule. This will be prepared by the contract manufacturer
         using a computerized random number generator, thereby guaranteeing full allocation
         concealment. Study medication will be issued in numerical order by the pharmacy. Participants
         in each site will be randomly assigned to the intervention arm or the placebo arm
         in a ratio of 1:1, and the randomization will be double-blind.
      </p>
      <h4>Blinding</h4>
      <p style="line-height:160%">Investigators and participants will remain blinded throughout the trial. Emergency
         unblinding will be allowed in limited situations that impact on the safety of study
         participants. Code-break envelopes for the full randomization schedule will be maintained
         by the Leeds General Infirmary pharmacy, and pharmacies at other sites will hold code-break
         envelopes for their respective participants. A 24-hour code-break telephone line will
         also be established in case of the need for emergency out-of-hours unblinding. Participants
         who are unblinded will be withdrawn from treatment but will continue to be followed
         as per the planned follow-up schedule, unless they request to fully withdraw from
         the trial.
      </p>
      <h4>Maintaining the treatment blind</h4>
      <p style="line-height:160%">Given the possible toxicities related to MTX, there is potential for investigators
         reviewing blood results to become aware of treatment. Therefore, patient-reported
         outcomes will be completed before any changes in dose or results of blood monitoring
         are discussed with participants. Where possible, members of staff with knowledge of
         blood results will not be responsible for administering patient questionnaires.
      </p>
      <h4>Data collection</h4>
      <p style="line-height:160%">All data will be collected on standardized CRFs, which will be completed by site staff,
         verified by the principal investigator, and returned to the clinical trials unit for
         data entry. Study sites will also return a patient non-identifiable participant log
         and study drug dispensing log to the clinical trials unit.
      </p>
      <h4>Patient reported, clinical and imaging assessments</h4>
      <p style="line-height:160%">In addition to the patient-reported measures of pain, function and quality-of-life
         and imaging outcome measures described above and outlined in Table&nbsp;<a name="d3712e1617"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/77/table/T2','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/77/table/T2">2</a>, a number of additional data elements will be collected during the trial. At the
         baseline visit, medical history and demographic data, including smoking and alcohol
         consumption, employment and family history of knee OA will be collected. Physical
         examination and vital signs, including height and weight, will be collected at screening,
         six and 12&nbsp;months. A clinical examination of the knee will also be conducted at the
         baseline visit. This will assess effusion on a zero to three scale, where one is positive
         bulge sign, two is positive fluctuance (balloon sign) and three is tense effusion,
         and compartmental (medial tibiofemoral (MTF), lateral tibiofemoral (LTF) or patellofemoral
         (PF)) tenderness, also measured on a zero to three scale. The specific tools used
         to capture each data element are further detailed in Table&nbsp;<a name="d3712e1620"></a><a onclick="popup('http://www.trialsjournal.com/content/16/1/77/table/T2','',800,470); return false;" href="http://www.trialsjournal.com/content/16/1/77/table/T2">2</a>.
      </p>
      <h4>Safety assessments</h4>
      <p style="line-height:160%">Adverse events will be recorded throughout the study. Intensity and relationship to
         the study medication will be ascribed.
      </p>
      <h4>Blood and urine safety assessment</h4>
      <p style="line-height:160%">Safety of therapy will be assessed according to regional monitoring guidelines and
         will be determined by treatment strategy. Full blood count (FBC), liver function test
         (LFT) and urea and electrolytes (U&amp;E) tests will be performed at screening, every
         two weeks for the first eight weeks, and every four weeks thereafter. If a patient’s
         results remain abnormal despite action (such as reducing their MTX dose), or at clinician
         discretion, then study medication will be stopped. For the purposes of this study,
         abnormal is defined as: haemoglobin ≤8.5&nbsp;g/dL; white cell count (WCC) ≤3.5 × 10<sup>9</sup>/L; neutrophils ≤1.5 × 10<sup>9</sup>/L; platelets ≤100 × 10<sup>9</sup>/L; alanine aminotransferase (ALT) &gt; two times the upper limit of normal (ULN) for
         the laboratory conducting the test; creatinine &gt;1.5 times the ULN for the laboratory
         conducting the test and estimated glomerular filtration rate (eGFR) &lt;30&nbsp;mL/minute.
      </p>
      <p style="line-height:160%">C-reactive protein (CRP), anti-cyclic citrullinated protein (anti-CCP) and rheumatoid
         factor (RF) tests will be performed at screening. Anti-CCP and RF results from the
         previous 12&nbsp;months may be used if these are available. A dipstick urinalysis will
         be performed at screening to check for evidence of leucocytes, blood or protein, to
         exclude urine infection. A urine dipstick pregnancy test will be performed for female
         participants with child-bearing potential, and appropriate contraceptive methods documented
         for those at risk.
      </p>
      <h4>Data integrity and management</h4>
      <p style="line-height:160%">All data obtained will be kept strictly confidential and will be stored electronically
         on a database with secured and restricted access. Datasets for each subject will be
         identified by the participant trial identification number only.
      </p>
      <h4>Withdrawal</h4>
      <p style="line-height:160%">All participants have the right to withdraw consent at any time without prejudice.
         At the time of withdrawal of consent, a full efficacy and safety evaluation should
         be performed if the participant consents. Participants who withdraw will be asked
         to complete the questionnaires as per the next planned study visit. At a participant’s
         request, their data collected up to the point of withdrawal can also be withdrawn
         from the trial and will not be used in the final analysis. Participants who withdraw
         will return to routine care in the rheumatology and musculoskeletal out-patient clinics.
      </p>
      <p style="line-height:160%">In the event that a patient is unable to tolerate 7.5&nbsp;mg of MTX, they will be withdrawn
         from treatment but will continue to be followed up on as per the planned follow-up
         schedule, unless they request to fully withdraw from the trial.
      </p>
      <h4>Study site staff training</h4>
      <p style="line-height:160%">A centralized introduction and training session was held for all principal investigators
         and site staff. In addition to this, a site initiation visit will be held at all sites,
         in order to provide specific training to all staff involved in the study ahead of
         recruitment. Pre-study training will be conducted to ensure robustness of MRI acquisition.
      </p>
      <h4>Trial site monitoring</h4>
      <p style="line-height:160%">The trial will be overseen and monitored by the York Trials Unit on behalf of the
         Sponsor, the University of Leeds. Each site will be assessed prior to site setup,
         and visited again once the third participant is recruited or at 20&nbsp;weeks after the
         start of recruitment at site, whichever is sooner. The PROMOTE trial was assessed
         as low risk by the Medicines and Healthcare Products Regulatory Agency (MHRA), and
         therefore in addition to the single monitoring visit, procedures for central monitoring
         at the clinical trials unit have been put in place. This will mainly involve cross-checking
         logs returned from the research team and site pharmacy for consistency. A data monitoring
         and ethics committee will provide independent oversight to ensure data quality and
         compliance with the trial protocol.
      </p>
      <h4>Statistical analysis</h4>
      <p style="line-height:160%">Full details of the statistical methods will be written in an approved statistical
         analysis plan prior to any data analysis.
      </p>
      <h4>Primary endpoint analysis</h4>
      <p style="line-height:160%">The primary analysis will be conducted on the intention-to-treat population, including
         all randomized participants in the groups to which they were randomized. A per protocol
         population (excluding major protocol violations) will be used to check the robustness
         of the primary analyses. The safety population will consist of all patients receiving
         at least one dose of the study drug.
      </p>
      <p style="line-height:160%">The first 30 participants (included in the internal pilot study) will be included
         in the main trial analysis along with the rest of the participants. Wittes and Brittain
         show that sample size re-estimation using an internal pilot study has minimum impact
         on the overall type I error, therefore an alpha level of 0.05 will still be used for
         the primary analysis <a name="d3712e1687"></a>[<a onclick="LoadInParent('#B57'); return false;" href="#B57">57</a>].
      </p>
      <p style="line-height:160%">The pilot phase analysis, which will be conducted after primary outcome data becomes
         available for the thirtieth participant, will include the following:
      </p>
      <p style="line-height:160%">1. Assessment of the variability of the primary outcome measure, the estimate (SD)
         will be used to update the sample size calculation;
      </p>
      <p style="line-height:160%">2. Consent rate (out of the number of information packs sent out during the pilot
         phase);
      </p>
      <p style="line-height:160%">3. Retention rates associated with each treatment and</p>
      <p style="line-height:160%">4. Return rate for the six-month outcome assessment.</p>
      <p style="line-height:160%">The primary analysis for the main study will be conducted using linear regression
         adjusting for the baseline measure. Treatment groups will be compared at six months
         with respect to their average overall knee pain severity over the previous week.
      </p>
      <p style="line-height:160%">All secondary analyses will be conducted using linear or logistic regression, depending
         on the type of outcome measure, adjusting for the same covariates as the primary analysis.
         The intention-to-treat population will be used for all secondary analyses. All secondary
         outcomes will be described descriptively (mean, SD, median, minimum and maximum for
         continuous data and counts and percentages for categorical data). The Short Form-12
         questionnaire will be summarized for all components. To minimise multiple testing,
         only the overall physical component score and mental component score will be analysed,
         using the same analysis methods as for the primary outcome. For continuous outcomes
         the regression model assumptions will be checked and, if necessary, data will be transformed
         prior to analysis if this improves the model fit, or normalises the distribution of
         residuals.
      </p>
      <p style="line-height:160%">Adverse events will be coded according to the MedDRA adverse event dictionary. The
         overall incidence of serious adverse events and adverse events and number and proportion
         of patients reporting such events will be summarized by treatment group. Adverse events
         (including serious adverse events) will be summarized by the number and percentage
         of subjects who experienced the event by system organ class and preferred term. Subjects
         will only be counted once. If a subject reports the same adverse event more than once
         then the maximum grade and strongest causal relationship to study treatment will be
         used for the summary tables. Adverse events will also be summarized by severity and
         by relationship to study drug. All adverse events will be included in individual subject
         line listings.
      </p>
      <p style="line-height:160%">Analysis of MRI endpoints will be exploratory. Treatment groups will be compared with
         respect to changes in synovitis, cartilage and bone using linear regression models
         with adjustment for the same covariates as the primary analysis. Linear regression
         models will also be used to explore the association between symptom outcome and baseline
         MRI measurements. Changes in MR features and the relationship of these changes with
         symptom changes will be explored descriptively.
      </p>
      <h4>Health economics analysis</h4>
      <p style="line-height:160%">An economic analysis will be undertaken in order to determine the cost-effectiveness
         of oral MTX for the treatment of knee OA. A cost-utility analysis will also be undertaken
         to explore the impact on health-related quality of life. The analyses will be conducted
         from the perspective of the United Kingdom NHS and Personal Social Services (PSS),
         in line with National Institute for Health and Care Excellence recommendations <a name="d3712e1716"></a>[<a onclick="LoadInParent('#B58'); return false;" href="#B58">58</a>].
      </p>
      <p style="line-height:160%">Health benefits for the economic evaluation will be measured in terms of pain reduction
         and QALYs. The QALY is a generic outcome which enables decision makers to compare
         across different disease areas. QALYs will be generated from the EuroQol EQ-5D-5&nbsp;L
         for use in the cost-utility analysis, and will be estimated by measuring the area
         under the curve <a name="d3712e1722"></a>[<a onclick="LoadInParent('#B59'); return false;" href="#B59">59</a>]. Utility data will be collected at the same time points as for clinical outcomes
         (at baseline, six months and 12&nbsp;months).
      </p>
      <p style="line-height:160%">Costs of the intervention, control and the total health care costs during the treatment
         and follow-up period will be assessed, including costs of adverse events and medications.
         Health service resource use will be collected via a self-reported resource use questionnaire,
         with national costs applied to the quantities of resources utilized, for example using
         NHS Reference Costs <a name="d3712e1728"></a>[<a onclick="LoadInParent('#B60'); return false;" href="#B60">60</a>] and Unit Costs of Health and Social Care <a name="d3712e1732"></a>[<a onclick="LoadInParent('#B61'); return false;" href="#B61">61</a>]. The unit costs of medications will be sourced from the British National Formulary
         <a name="d3712e1736"></a>[<a onclick="LoadInParent('#B62'); return false;" href="#B62">62</a>].
      </p>
      <p style="line-height:160%">The within-trial analysis will use regression methods to allow for the correlation
         between cost and outcome data generated from the trial, with adjustment for covariates.
         A cost-effectiveness analysis will determine the cost per unit of reduction in knee
         pain score (as measured on the NRS). A cost-utility analysis will be undertaken to
         generate the cost per QALY. The results will be presented in terms of incremental
         cost-effectiveness ratios (ICERs). Future costs and outcomes will not be discounted
         due to the trial follow-up being one year. Cost-effectiveness acceptability curves
         will be produced to explore the probability that MTX will be cost-effective at different
         cost-effectiveness thresholds <a name="d3712e1742"></a>[<a onclick="LoadInParent('#B63'); return false;" href="#B63">63</a>].
      </p>
   </div>
</section>
<section><a name="sec3"></a><h3>Discussion</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">Current medical therapy does not provide satisfactory pain relief in the majority
         of people with OA <a name="d3712e1752"></a>[<a onclick="LoadInParent('#B64'); return false;" href="#B64">64</a>]; with the rapidly ageing population the prevalence of OA will continue to rise over
         the next decade. Unless the barriers to successful treatment of OA are overcome, the
         already considerable social and economic burden will soon reach an unsustainable level.
         The last decade has seen major advances in understanding OA pathology. MRI has demonstrated
         that synovial inflammation is common in OA and is related to symptoms. MTX is the
         most common agent used to treat synovitis in RA and because of its favourable efficacy,
         long-term retention rates, low cost and established track record it has become the
         standard by which other DMARDs are evaluated, supporting our choice to use MTX rather
         than any other DMARD for a trial in OA. Since the design of this study and conduct
         of the systematic literature review, a single-centre randomized controlled trial of
         MTX in knee OA has been published <a name="d3712e1756"></a>[<a onclick="LoadInParent('#B65'); return false;" href="#B65">65</a>]. The study demonstrated a clinically relevant reduction in knee pain and physical
         function in the intervention group compared with the placebo group at 28&nbsp;weeks. A
         significantly higher proportion of patients in the MTX group (53%) showed a reduction
         in VAS of more than 20&nbsp;mm compared to the placebo group (24%; <em>P</em> = 0.018). The positive findings of this study reinforce the potential of MTX as a
         treatment for OA. However, given the substantial impact that using MTX for treating
         OA would have on clinical practice, a large multi-centre confirmatory study is essential.
         The PROMOTE trial has been designed to be pragmatic in nature so as to answer the
         question as to whether MTX is a valuable addition to the overall management of patients
         with OA.
      </p>
   </div>
</section>
<section><a name="sec4"></a><h3>Trial status</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">Recruitment to the trial began in June 2014. Follow-up of participants is in progress
         and is expected to be completed in December 2016.
      </p>
   </div>
</section>
<section><a name="sec5"></a><h3>Abbreviations</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">AICAR: Aminoimidazole carboxamide ribonucleotide</p>
      <p style="line-height:160%">ALT: Alanine aminotransferase</p>
      <p style="line-height:160%">CCG: Clinical Commissioning Group</p>
      <p style="line-height:160%">CCP: Cyclic citrullinated protein</p>
      <p style="line-height:160%">CCRN: Comprehensive Clinical Research Network</p>
      <p style="line-height:160%">CPPD: Calcium pyrophosphate crystal disease</p>
      <p style="line-height:160%">CRF: Case report form</p>
      <p style="line-height:160%">CRP: C-reactive protein</p>
      <p style="line-height:160%">CVD: Cardiovascular disease</p>
      <p style="line-height:160%">DMARD: Disease modifying anti-rheumatic drug</p>
      <p style="line-height:160%">eGFR: Estimated glomerular filtration rate</p>
      <p style="line-height:160%">FBC: Full blood count</p>
      <p style="line-height:160%">GP: General practitioner</p>
      <p style="line-height:160%">HADS: Hospital Anxiety and Depression Scale</p>
      <p style="line-height:160%">IA: Intra-articular</p>
      <p style="line-height:160%">ICER: Incremental cost-effectiveness ratio</p>
      <p style="line-height:160%">ICOAP: Intermittent and Constant Osteoarthritis Pain</p>
      <p style="line-height:160%">IL: Interleukin</p>
      <p style="line-height:160%">LFT: Liver function test</p>
      <p style="line-height:160%">LTF: Lateral tibiofemoral</p>
      <p style="line-height:160%">MHRA: Medicines and Healthcare Products Regulatory Agency</p>
      <p style="line-height:160%">MOAKS: MRI Osteoarthritis Knee Score</p>
      <p style="line-height:160%">MRI: Magnetic resonance imaging</p>
      <p style="line-height:160%">MTF: Medial tibiofemoral</p>
      <p style="line-height:160%">MTX: Methotrexate</p>
      <p style="line-height:160%">NHS: National Health Service</p>
      <p style="line-height:160%">NICE: National Institute for Health and Care Excellence</p>
      <p style="line-height:160%">NIMP: Non-Investigational Medicinal Product</p>
      <p style="line-height:160%">NRS: Numerical rating scale</p>
      <p style="line-height:160%">NSAID: Non-steroidal anti-inflammatory drug</p>
      <p style="line-height:160%">OA: Osteoarthritis</p>
      <p style="line-height:160%">OA QoL: Osteoarthritis Quality of Life Scale</p>
      <p style="line-height:160%">PF: Patellofemoral</p>
      <p style="line-height:160%">PICS: Patient Identification Centres</p>
      <p style="line-height:160%">PsA: Psoriatic arthritis</p>
      <p style="line-height:160%">PSS: Personal Social Services</p>
      <p style="line-height:160%">QALY: Quality-adjusted life year</p>
      <p style="line-height:160%">RA: Rheumatoid arthritis</p>
      <p style="line-height:160%">RF: Rheumatoid factor</p>
      <p style="line-height:160%">SD: Standard deviation</p>
      <p style="line-height:160%">TNF: Tumour necrosis factor</p>
      <p style="line-height:160%">U&amp;E: Urea and electrolytes</p>
      <p style="line-height:160%">ULN: Upper limit of normal</p>
      <p style="line-height:160%">VAS: Visual analogue scale</p>
      <p style="line-height:160%">WCC: White cell count</p>
      <p style="line-height:160%">WOMAC: Western Ontario and McMaster Universities Index of OA</p>
   </div>
</section>
<section><a name="sec6"></a><h3>Competing interests</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">The authors declare they have no competing interests.</p>
   </div>
</section>
<section><a name="sec7"></a><h3>Authors’ contributions</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">PGC conceived the study. SRK, PT, NKA, MB, FB, KC, MD, CJE, TG, AJG, MG, CEH,RH, RM,
         TWO, ER, DLS, FEW, DJT and PGC participated in its design and coordination, and performed
         the research. SRK and PT drafted the manuscript. All authors revised the manuscript
         and gave final approval of the version to be submitted.
      </p>
   </div>
</section>
<section><a name="ack"></a><h3>Acknowledgements</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">The PROMOTE trial is funded by an Arthritis Research UK Clinical Studies Grant (reference
         number: 20186). The authors acknowledge the support of the National Institute for
         Health Research, through the Comprehensive Clinical Research Network (CCRN). Please
         do not hesitate to contact the CCRN Portfolio team at ccrn.portfolio@nihr.ac.uk should
         you require further information.
      </p>
      <p style="line-height:160%">SRK and PGC are part funded by the National Institute for Health Research (NIHR) through
         the Leeds Musculoskeletal Biomedical Research Unit. This paper presents independent
         research funded by the NIHR. The views expressed are those of the authors and not
         necessarily those of the NHS, the NIHR or the Department of Health.
      </p>
   </div>
</section>
<section><a name="refs"></a><h3>References</h3>
   <div id="article-references" class="collapsible-content">
      <ol id="references">
         <li id="B1">
            <p><a name="B1"></a> Murray CJ,  Vos T,  Lozano R,  Naghavi M,  Flaxman AD,  Michaud C, <em>et al</em>.: <strong> Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions,
                  1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. </strong><p><em>Lancet</em> 2012,  <strong>380</strong>(9859)<strong>:</strong>2197-223. 
               <p> doi:10.1016/S0140-6736(12)61689-4</p> <a target="_blank" href="/pubmed/23245608">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=23245608">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B1" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B1','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B2">
            <p><a name="B2"></a> Vos T,  Flaxman AD,  Naghavi M,  Lozano R,  Michaud C,  Ezzati M, <em>et al</em>.: <strong> Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries
                  1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. </strong><p><em>Lancet</em> 2012,  <strong>380</strong>(9859)<strong>:</strong>2163-96. 
               <p> doi:10.1016/S0140-6736(12)61729-2</p> <a target="_blank" href="/pubmed/23245607">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=23245607">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B2" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B2','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B3">
            <p><a name="B3"></a> Murphy L,  Schwartz TA,  Helmick CG,  Renner JB,  Tudor G,  Koch G, <em>et al</em>.: <strong> Lifetime risk of symptomatic knee osteoarthritis. </strong><p><em>Arthritis Rheum</em> 2008,  <strong>59</strong>(9)<strong>:</strong>1207-13. 
               <p> doi:10.1002/art.24021</p> <a target="_blank" href="/pubmed/18759314">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=18759314">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B3" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B3','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B4">
            <p><a name="B4"></a> Bitton R: <strong> The economic burden of osteoarthritis. </strong><p><em>Am J Manag Care</em> 2009,  <strong>15</strong>(Suppl 8)<strong>:</strong>S230-5.  <a target="_blank" href="/pubmed/19817509">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=19817509">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B4" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B4','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B5">
            <p><a name="B5"></a> Care A: <p><em>OA Nations Survey</em>. 2003. <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B5" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B5','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B6">
            <p><a name="B6"></a> Hiligsmann M,  Cooper C,  Arden N,  Boers M,  Branco JC,  Luisa Brandi M, <em>et al</em>.: <strong> Health economics in the field of osteoarthritis: An Expert’s consensus paper from
                  the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis
                  (ESCEO). </strong><p><em>Semin Arthritis Rheum</em> 2013,  <strong>43</strong>(3)<strong>:</strong>303-13. 
               <p> doi:10.1016/j.semarthrit.2013.07.003</p> <a target="_blank" href="/pubmed/23992801">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=23992801">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B6" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B6','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B7">
            <p><a name="B7"></a>National Institute for Health and Care Excellence. Osteoarthritis: care and management
               in adults. NICE Clinical Guideline 177. February 2014. http://www.nice.org.uk/guidance/CG177.
               Accessed 4 Aug 2014.
            </p>
         </li>
         <li id="B8">
            <p><a name="B8"></a> McAlindon TE,  Bannuru RR,  Sullivan MC,  Arden NK,  Berenbaum F,  Bierma-Zeinstra SM, <em>et al</em>.: <strong> OARSI guidelines for the non-surgical management of knee osteoarthritis. </strong><p><em>Osteoarthritis Cartilage</em> 2014,  <strong>22</strong>(3)<strong>:</strong>363-88. 
               <p> doi:10.1016/j.joca.2014.01.003</p> <a target="_blank" href="/pubmed/24462672">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=24462672">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B8" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B8','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B9">
            <p><a name="B9"></a> Hochberg MC,  Altman RD,  April KT,  Benkhalti M,  Guyatt G,  McGowan J, <em>et al</em>.: <strong> American College of Rheumatology 2012 recommendations for the use of nonpharmacologic
                  and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. </strong><p><em>Arthritis Care Res (Hoboken)</em> 2012,  <strong>64</strong>(4)<strong>:</strong>465-74.   <a target="_blank" href="http://dx.doi.org/10.1002/acr.21596">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B9" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B9','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B10">
            <p><a name="B10"></a>Conaghan PG, Porcheret M, Kingsbury SR, Gammon A, Soni A, Hurley M et al. Impact and
               therapy of osteoarthritis: the Arthritis Care OA Nation 2012 survey. Clin Rheumatol.
               2014. doi:10.1007/s10067-014-2692-1.
            </p>
         </li>
         <li id="B11">
            <p><a name="B11"></a>National population projections, 2008-based. Office for National Statistics. 2009.
               http://www.ons.gov.uk/ons/rel/npp/national-population-projections/2008-based-projections/index.html.
               Accessed 19 Feb 2015.
            </p>
         </li>
         <li id="B12">
            <p><a name="B12"></a>Proceedings of the bone and joint decade 2000–2010 for prevention and treatment of
               musculo-skeletal disorders; 1998 April 17–18; Lund, Sweden. Acta Orthop Scand Suppl.
               1998;281:1–86.
            </p>
         </li>
         <li id="B13">
            <p><a name="B13"></a> D’Agostino MA,  Conaghan P,  Le Bars M,  Baron G,  Grassi W,  Martin-Mola E, <em>et al</em>.: <strong> EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 1:
                  prevalence of inflammation in osteoarthritis. </strong><p><em>Ann Rheum Dis</em> 2005,  <strong>64</strong>(12)<strong>:</strong>1703-9. 
               <p> doi:10.1136/ard.2005.037994</p> <a target="_blank" href="/pubmed/15878903">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=15878903">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B13" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B13','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B14">
            <p><a name="B14"></a> Ostergaard M,  Stoltenberg M,  Lovgreen-Nielsen P,  Volck B,  Jensen CH,  Lorenzen I: <strong> Magnetic resonance imaging-determined synovial membrane and joint effusion volumes
                  in rheumatoid arthritis and osteoarthritis: comparison with the macroscopic and microscopic
                  appearance of the synovium. </strong><p><em>Arthritis Rheum</em> 1997,  <strong>40</strong>(10)<strong>:</strong>1856-67. 
               <p> doi:10.1002/1529-0131(199710)40:10&lt;1856::AID-ART20&gt;3.0.CO;2-3</p> <a target="_blank" href="/pubmed/9336422">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=9336422">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B14" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B14','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B15">
            <p><a name="B15"></a> Peterfy CG,  Majumdar S,  Lang P,  van Dijke CF,  Sack K,  Genant HK: <strong> MR imaging of the arthritic knee: improved discrimination of cartilage, synovium,
                  and effusion with pulsed saturation transfer and fat-suppressed T1-weighted sequences. </strong><p><em>Radiology</em> 1994,  <strong>191</strong>(2)<strong>:</strong>413-9.  <a target="_blank" href="/pubmed/8153315">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=8153315">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B15" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B15','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B16">
            <p><a name="B16"></a> Keen HI,  Wakefield RJ,  Grainger AJ,  Hensor EM,  Emery P,  Conaghan PG: <strong> An ultrasonographic study of osteoarthritis of the hand: synovitis and its relationship
                  to structural pathology and symptoms. </strong><p><em>Arthritis Rheum</em> 2008,  <strong>59</strong>(12)<strong>:</strong>1756-63. 
               <p> doi:10.1002/art.24312</p> <a target="_blank" href="/pubmed/19035429">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=19035429">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B16" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B16','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B17">
            <p><a name="B17"></a> Hill CL,  Gale DG,  Chaisson CE,  Skinner K,  Kazis L,  Gale ME, <em>et al</em>.: <strong> Knee effusions, popliteal cysts, and synovial thickening: association with knee pain
                  in osteoarthritis. </strong><p><em>J Rheumatol</em> 2001,  <strong>28</strong>(6)<strong>:</strong>1330-7.  <a target="_blank" href="/pubmed/11409127">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=11409127">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B17" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B17','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B18">
            <p><a name="B18"></a> Hill CL,  Hunter DJ,  Niu J,  Clancy M,  Guermazi A,  Genant H, <em>et al</em>.: <strong> Synovitis detected on magnetic resonance imaging and its relation to pain and cartilage
                  loss in knee osteoarthritis. </strong><p><em>Ann Rheum Dis</em> 2007,  <strong>66</strong>(12)<strong>:</strong>1599-603. 
               <p> doi:10.1136/ard.2006.067470</p> <a target="_blank" href="/pubmed/17491096">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=17491096">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B18" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B18','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B19">
            <p><a name="B19"></a> Goldring MB: <strong> Anticytokine therapy for osteoarthritis. </strong><p><em>Expert Opin Biol Ther</em> 2001,  <strong>1</strong>(5)<strong>:</strong>817-29. 
               <p> doi:10.1517/14712598.1.5.817</p> <a target="_blank" href="/pubmed/11728217">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=11728217">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B19" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B19','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B20">
            <p><a name="B20"></a> Smith MD,  Triantafillou S,  Parker A,  Youssef PP,  Coleman M: <strong> Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. </strong><p><em>J Rheumatol</em> 1997,  <strong>24</strong>(2)<strong>:</strong>365-71.  <a target="_blank" href="/pubmed/9034998">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=9034998">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B20" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B20','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B21">
            <p><a name="B21"></a> Myers SL,  Brandt KD,  Ehlich JW,  Braunstein EM,  Shelbourne KD,  Heck DA, <em>et al</em>.: <strong> Synovial inflammation in patients with early osteoarthritis of the knee. </strong><p><em>J Rheumatol</em> 1990,  <strong>17</strong>(12)<strong>:</strong>1662-9.  <a target="_blank" href="/pubmed/2084242">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=2084242">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B21" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B21','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B22">
            <p><a name="B22"></a> Brandt KD,  Mazzuca SA,  Buckwalter KA: <strong> Acetaminophen, like conventional NSAIDs, may reduce synovitis in osteoarthritic knees. </strong><p><em>Rheumatology (Oxford)</em> 2006,  <strong>45</strong>(11)<strong>:</strong>1389-94. 
               <p> doi:10.1093/rheumatology/kel100</p>  <a target="_blank" href="http://dx.doi.org/10.1093/rheumatology/kel100">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B22" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B22','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B23">
            <p><a name="B23"></a> Gineyts E,  Mo JA,  Ko A,  Henriksen DB,  Curtis SP,  Gertz BJ, <em>et al</em>.: <strong> Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients
                  with knee osteoarthritis. </strong><p><em>Ann Rheum Dis</em> 2004,  <strong>63</strong>(7)<strong>:</strong>857-61. 
               <p> doi:10.1136/ard.2003.007302</p> <a target="_blank" href="/pubmed/15194584">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=15194584">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B23" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B23','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B24">
            <p><a name="B24"></a> Felson DT,  Lawrence RC,  Dieppe PA,  Hirsch R,  Helmick CG,  Jordan JM, <em>et al</em>.: <strong> Osteoarthritis: new insights. Part 1: the disease and its risk factors. </strong><p><em>Ann Intern Med</em> 2000,  <strong>133</strong>(8)<strong>:</strong>635-46. 
               <p> doi:200010170–00016</p> <a target="_blank" href="/pubmed/11033593">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=11033593">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B24" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B24','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B25">
            <p><a name="B25"></a> Ravaud P,  Moulinier L,  Giraudeau B,  Ayral X,  Guerin C,  Noel E, <em>et al</em>.: <strong> Effects of joint lavage and steroid injection in patients with osteoarthritis of the
                  knee: results of a multicenter, randomized, controlled trial. </strong><p><em>Arthritis Rheum</em> 1999,  <strong>42</strong>(3)<strong>:</strong>475-82. 
               <p> doi:10.1002/1529-0131(199904)42:3&lt;475::AID-ANR12&gt;3.0.CO;2-S</p> <a target="_blank" href="/pubmed/10088770">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=10088770">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B25" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B25','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B26">
            <p><a name="B26"></a> Bellamy N,  Campbell J,  Robinson V,  Gee T,  Bourne R,  Wells G: <strong> Intraarticular corticosteroid for treatment of osteoarthritis of the knee. </strong><p><em>Cochrane Database Syst Rev</em> 2006.,  <strong>2</strong><p>Article ID CD005328 doi:10.1002/14651858.CD005328.pub2</p> <a target="_blank" href="/pubmed/16625636">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=16625636">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B26" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B26','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B27">
            <p><a name="B27"></a> Jones A,  Doherty M: <strong> Intra-articular corticosteroids are effective in osteoarthritis but there are no clinical
                  predictors of response. </strong><p><em>Ann Rheum Dis</em> 1996,  <strong>55</strong>(11)<strong>:</strong>829-32.  <a target="_blank" href="/pubmed/8976640">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=8976640">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B27" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B27','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B28">
            <p><a name="B28"></a> Hochberg MC,  Altman RD,  April KT,  Benkhalti M,  Guyatt G,  McGowan J, <em>et al</em>.: <strong> American College of Rheumatology 2012 recommendations for the use of nonpharmacologic
                  and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. </strong><p><em>Arthritis Care Res</em> 2012,  <strong>64</strong>(4)<strong>:</strong>455-74.   <a target="_blank" href="http://dx.doi.org/10.1002/acr.21596">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B28" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B28','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B29">
            <p><a name="B29"></a> Westlake SL,  Colebatch AN,  Baird J,  Kiely P,  Quinn M,  Choy E, <em>et al</em>.: <strong> The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis:
                  a systematic literature review. </strong><p><em>Rheumatology (Oxford)</em> 2010,  <strong>49</strong>(2)<strong>:</strong>295-307. 
               <p> doi:10.1093/rheumatology/kep366</p>  <a target="_blank" href="http://dx.doi.org/10.1093/rheumatology/kep366">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B29" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B29','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B30">
            <p><a name="B30"></a> Mease P: <strong> Methotrexate in psoriatic arthritis. </strong><p><em>Bull Hosp Jt Dis (2013)</em> 2013,  <strong>71</strong>(Suppl 1)<strong>:</strong>S41-5.  <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B30" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B30','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B31">
            <p><a name="B31"></a> Hasko G,  Cronstein BN: <strong> Adenosine: an endogenous regulator of innate immunity. </strong><p><em>Trends Immunol</em> 2004,  <strong>25</strong>(1)<strong>:</strong>33-9. 
               <p> doi:S1471490603003582</p> <a target="_blank" href="/pubmed/14698282">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=14698282">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B31" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B31','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B32">
            <p><a name="B32"></a> Cronstein BN: <strong> Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. </strong><p><em>Pharmacol Rev</em> 2005,  <strong>57</strong>(2)<strong>:</strong>163-72. 
               <p> doi:10.1124/pr.57.2.3</p> <a target="_blank" href="/pubmed/15914465">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=15914465">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B32" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B32','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B33">
            <p><a name="B33"></a> Weinblatt ME,  Kaplan H,  Germain BF,  Block S,  Solomon SD,  Merriman RC, <em>et al</em>.: <strong> Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. </strong><p><em>Arthritis Rheum</em> 1994,  <strong>37</strong>(10)<strong>:</strong>1492-8.  <a target="_blank" href="/pubmed/7945475">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=7945475">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B33" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B33','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B34">
            <p><a name="B34"></a> van Ede AE,  Laan RF,  Rood MJ,  Huizinga TW,  van de Laar MA,  van Denderen CJ, <em>et al</em>.: <strong> Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate
                  in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind,
                  placebo-controlled study. </strong><p><em>Arthritis Rheum</em> 2001,  <strong>44</strong>(7)<strong>:</strong>1515-24. 
               <p> doi:10.1002/1529-0131(200107)44:7&lt;1515::AID-ART273&gt;3.0.CO;2-7</p> <a target="_blank" href="/pubmed/11465701">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=11465701">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B34" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B34','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B35">
            <p><a name="B35"></a> Schnabel A,  Herlyn K,  Burchardi C,  Reinhold-Keller E,  Gross WL: <strong> Long-term tolerability of methotrexate at doses exceeding 15&nbsp;mg per week in rheumatoid
                  arthritis. </strong><p><em>Rheumatol Int</em> 1996,  <strong>15</strong>(5)<strong>:</strong>195-200.  <a target="_blank" href="/pubmed/8717103">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=8717103">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B35" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B35','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B36">
            <p><a name="B36"></a> Salaffi F,  Carotti M,  Sartini A,  Cervini C: <strong> A prospective study of the long-term efficacy and toxicity of low-dose methotrexate
                  in rheumatoid arthritis. </strong><p><em>Clin Exp Rheumatol</em> 1995,  <strong>13</strong>(1)<strong>:</strong>23-8.  <a target="_blank" href="/pubmed/7774099">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=7774099">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B36" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B36','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B37">
            <p><a name="B37"></a> de Holanda HT,  Pollak DF,  Pucinelli ML: <strong> Low-dose methotrexate compared to placebo in the treatment of knee osteoarthritis. </strong><p><em>Rev Bras Reumatol</em> 2007,  <strong>47</strong>(5)<strong>:</strong>334-40.   <a target="_blank" href="http://dx.doi.org/10.1590/S0482-50042007000500008">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B37" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B37','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B38">
            <p><a name="B38"></a> Pavelka K,  Olejarova M,  Pavelkova A: <strong> Methotrexate in the treatment of erosive OA of the hands. </strong><p><em>Ann Rheum Dis</em> 2006,  <strong>65</strong>(Suppl II)<strong>:</strong>402.  <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B38" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B38','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B39">
            <p><a name="B39"></a> Chollet-Janin A,  Finckh A,  Dudler J,  Guerne PA: <strong> Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition
                  disease: an exploratory analysis. </strong><p><em>Arthritis Rheum</em> 2007,  <strong>56</strong>(2)<strong>:</strong>688-92. 
               <p> doi:10.1002/art.22389</p> <a target="_blank" href="/pubmed/17265505">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=17265505">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B39" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B39','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B40">
            <p><a name="B40"></a> Wenham CY,  Grainger AJ,  Hensor EM,  Caperon AR,  Ash ZR,  Conaghan PG: <strong> Methotrexate for pain relief in knee osteoarthritis: an open-label study. </strong><p><em>Rheumatology (Oxford)</em> 2013,  <strong>52</strong>(5)<strong>:</strong>888-92. 
               <p> doi:10.1093/rheumatology/kes386</p>  <a target="_blank" href="http://dx.doi.org/10.1093/rheumatology/kes386">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B40" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B40','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B41">
            <p><a name="B41"></a> Neidel J,  Schroers B,  Sintermann F: <strong> The effects of high-dose methotrexate on the development of cartilage lesions in a
                  lapine model of osteoarthrosis. </strong><p><em>Arch Orthop Trauma Surg</em> 1998,  <strong>117</strong>(4–5)<strong>:</strong>265-9.  <a target="_blank" href="/pubmed/9581258">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=9581258">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B41" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B41','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B42">
            <p><a name="B42"></a> Mannoni A,  Altman RD,  Muniz OE,  Serni U,  Dean DD: <strong> The effects of methotrexate on normal and osteoarthritic lapine articular cartilage. </strong><p><em>J Rheumatol</em> 1993,  <strong>20</strong>(5)<strong>:</strong>849-55.  <a target="_blank" href="/pubmed/8336311">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=8336311">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B42" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B42','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B43">
            <p><a name="B43"></a> Visser K,  Katchamart W,  Loza E,  Martinez-Lopez JA,  Salliot C,  Trudeau J, <em>et al</em>.: <strong> Multinational evidence-based recommendations for the use of methotrexate in rheumatic
                  disorders with a focus on rheumatoid arthritis: integrating systematic literature
                  research and expert opinion of a broad international panel of rheumatologists in the
                  3E Initiative. </strong><p><em>Ann Rheum Dis</em> 2009,  <strong>68</strong>(7)<strong>:</strong>1086-93. 
               <p> doi:10.1136/ard.2008.094474</p> <a target="_blank" href="/pubmed/19033291">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=19033291">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B43" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B43','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B44">
            <p><a name="B44"></a> Visser K,  van der Heijde D: <strong> Optimal dosage and route of administration of methotrexate in rheumatoid arthritis:
                  a systematic review of the literature. </strong><p><em>Ann Rheum Dis</em> 2009,  <strong>68</strong>(7)<strong>:</strong>1094-9. 
               <p> doi:10.1136/ard.2008.092668</p> <a target="_blank" href="/pubmed/19033290">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=19033290">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B44" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B44','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B45">
            <p><a name="B45"></a> Shea B,  Swinden MV,  Tanjong Ghogomu E,  Ortiz Z,  Katchamart W,  Rader T, <em>et al</em>.: <strong> Folic acid and folinic acid for reducing side effects in patients receiving methotrexate
                  for rheumatoid arthritis. </strong><p><em>Cochrane Database Syst Rev</em> 2013.,  <strong>5</strong><p>Article ID CD000951 doi:10.1002/14651858.CD000951.pub2</p> <a target="_blank" href="/pubmed/23728635">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=23728635">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B45" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B45','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B46">
            <p><a name="B46"></a> Chang L: <strong> A psychometric evaluation of 4-point and 6-point Likert-type scales in relation to
                  reliability and validity applied psychological measurements. </strong><p><em>Appl Psychol Meas</em> 1994,  <strong>18</strong>(3)<strong>:</strong>205-15.   <a target="_blank" href="http://dx.doi.org/10.1177/014662169401800302">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B46" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B46','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B47">
            <p><a name="B47"></a> Dworkin RH,  Peirce-Sandner S,  Turk DC,  McDermott MP,  Gibofsky A,  Simon LS, <em>et al</em>.: <strong> Outcome measures in placebo-controlled trials of osteoarthritis: responsiveness to
                  treatment effects in the REPORT database. </strong><p><em>Osteoarthritis Cartilage</em> 2014,  <strong>19</strong>(5)<strong>:</strong>483-92.   <a target="_blank" href="http://dx.doi.org/10.1016/j.joca.2011.02.020">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B47" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B47','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B48">
            <p><a name="B48"></a> Dworkin RH,  Turk DC,  Farrar JT,  Haythornthwaite JA,  Jensen MP,  Katz NP, <em>et al</em>.: <strong> Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. </strong><p><em>Pain</em> 2005,  <strong>113</strong>(1–2)<strong>:</strong>9-19. 
               <p> doi:10.1016/j.pain.2004.09.012</p> <a target="_blank" href="/pubmed/15621359">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=15621359">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B48" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B48','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B49">
            <p><a name="B49"></a> Turk DC,  Dworkin RH,  Allen RR,  Bellamy N,  Brandenburg N,  Carr DB, <em>et al</em>.: <strong> Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. </strong><p><em>Pain</em> 2003,  <strong>106</strong>(3)<strong>:</strong>337-45.  <a target="_blank" href="/pubmed/14659516">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=14659516">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B49" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B49','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B50">
            <p><a name="B50"></a> Turk DC,  Dworkin RH,  Revicki D,  Harding G,  Burke LB,  Cella D, <em>et al</em>.: <strong> Identifying important outcome domains for chronic pain clinical trials: an IMMPACT
                  survey of people with pain. </strong><p><em>Pain</em> 2008,  <strong>137</strong>(2)<strong>:</strong>276-85. 
               <p> doi:10.1016/j.pain.2007.09.002</p> <a target="_blank" href="/pubmed/17937976">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=17937976">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B50" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B50','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B51">
            <p><a name="B51"></a> Hunter DJ,  Guermazi A,  Lo GH,  Grainger AJ,  Conaghan PG,  Boudreau RM, <em>et al</em>.: <strong> Evolution of semi-quantitative whole joint assessment of knee OA: MOAKS (MRI Osteoarthritis
                  Knee Score). Osteoarthritis Cartilage. 2011;19(8):990–1002. Erratum in. </strong><p><em>Osteoarthritis Cartilage</em> 2011,  <strong>19</strong>(9)<strong>:</strong>1168.   <a target="_blank" href="http://dx.doi.org/10.1016/j.joca.2011.08.001">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B51" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B51','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B52">
            <p><a name="B52"></a> Bowes MA,  Vincent GR,  Wolstenholme CB,  Conaghan PG: <strong> A novel method for bone area measurement provides new insights into osteoarthritis
                  and its progression. </strong><p><em>Ann Rheum Dis</em> 2015,  <strong>74</strong>(3)<strong>:</strong>519-25. 
               <p> doi:10.1136/annrheumdis-2013-204052</p> <a target="_blank" href="/pubmed/24306109">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=24306109">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B52" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B52','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B53">
            <p><a name="B53"></a> Farrar JT,  Young JP Jr,  LaMoreaux L,  Werth JL,  Poole RM: <strong> Clinical importance of changes in chronic pain intensity measured on an 11-point numerical
                  pain rating scale. </strong><p><em>Pain</em> 2001,  <strong>94</strong>(2)<strong>:</strong>149-58.  <a target="_blank" href="/pubmed/11690728">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=11690728">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B53" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B53','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B54">
            <p><a name="B54"></a> Salaffi F,  Stancati A,  Silvestri CA,  Ciapetti A,  Grassi W: <strong> Minimal clinically important changes in chronic musculoskeletal pain intensity measured
                  on a numerical rating scale. </strong><p><em>Eur J Pain</em> 2004,  <strong>8</strong>(4)<strong>:</strong>283-91. 
               <p> doi:10.1016/j.ejpain.2003.09.004</p> <a target="_blank" href="/pubmed/15207508">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=15207508">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B54" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B54','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B55">
            <p><a name="B55"></a> Fukuda TY: <strong> Alves da Cunha R, Fukuda VO, Rienzo FA, Cazarini Jr C, Carvalho Nde A, et al. Pulsed
                  shortwave treatment in women with knee osteoarthritis: a multicenter, randomized,
                  placebo-controlled clinical trial. </strong><p><em>Phys Ther</em> 2011,  <strong>91</strong>(7)<strong>:</strong>1009-17. 
               <p> doi:10.2522/ptj.20100306</p> <a target="_blank" href="/pubmed/21642511">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=21642511">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B55" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B55','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B56">
            <p><a name="B56"></a> Bennell KL,  Bowles KA,  Payne C,  Cicuttini F,  Williamson E,  Forbes A, <em>et al</em>.: <strong> Lateral wedge insoles for medial knee osteoarthritis: 12&nbsp;month randomised controlled
                  trial. </strong><p><em>BMJ</em> 2011,  <strong>342</strong><strong>:</strong>d2912. 
               <p> doi:10.1136/bmj.d2912</p> <a target="_blank" href="/pubmed/21593096">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=21593096">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B56" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B56','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B57">
            <p><a name="B57"></a> Wittes J,  Brittain E: <strong> The role of internal pilot studies in increasing the efficiency of clinical trials. </strong><p><em>Stat Med</em> 1990,  <strong>9</strong>(1–2)<strong>:</strong>65-71. 
               <p> discussion 71–2</p> <a target="_blank" href="/pubmed/2345839">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=2345839">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B57" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B57','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B58">
            <p><a name="B58"></a>National Institute for Health and Care Excellence: 
               	<em>Guide to the methods of technology appraisal</em>.  NICE, London;  2008. <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B58" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B58','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B59">
            <p><a name="B59"></a> Murphy SL,  Lyden AK,  Smith DM,  Dong Q,  Koliba JF: <strong> Effects of a tailored activity pacing intervention on pain and fatigue for adults
                  with osteoarthritis. </strong><p><em>Am J Occup Ther</em> 2010,  <strong>64</strong>(6)<strong>:</strong>869-76.  <a target="_blank" href="/pubmed/21218677">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=21218677">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B59" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B59','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B60">
            <p><a name="B60"></a> Little CB,  Smith MM,  Cake MA,  Read RA,  Murphy MJ,  Barry FP: <strong> The OARSI histopathology initiative - recommendations for histological assessments
                  of osteoarthritis in sheep and goats. </strong><p><em>Osteoarthritis Cartilage</em> 2010,  <strong>18</strong>(Suppl 3)<strong>:</strong>S80-92. 
               <p> doi:10.1016/j.joca.2010.04.016</p> <a target="_blank" href="/pubmed/20864026">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=20864026">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B60" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B60','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B61">
            <p><a name="B61"></a> Murphy LB,  Helmick CG,  Schwartz TA,  Renner JB,  Tudor G,  Koch GG, <em>et al</em>.: <strong> One in four people may develop symptomatic hip osteoarthritis in his or her lifetime. </strong><p><em>Osteoarthritis Cartilage</em> 2010,  <strong>18</strong>(11)<strong>:</strong>1372-9. 
               <p> doi:10.1016/j.joca.2010.08.005</p> <a target="_blank" href="/pubmed/20713163">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=20713163">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B61" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B61','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B62">
            <p><a name="B62"></a> Coleman CM,  Curtin C,  Barry FP,  O’Flatharta C,  Murphy JM: <strong> Mesenchymal stem cells and osteoarthritis: remedy or accomplice? </strong><p><em>Hum Gene Ther</em> 2010,  <strong>21</strong>(10)<strong>:</strong>1239-50. 
               <p> doi:10.1089/hum.2010.138</p> <a target="_blank" href="/pubmed/20649459">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=20649459">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B62" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B62','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B63">
            <p><a name="B63"></a> Murphy CL: <strong> HIF-2alpha–a mediator of osteoarthritis? </strong><p><em>Cell Res</em> 2010,  <strong>20</strong>(9)<strong>:</strong>977-9. 
               <p> doi:10.1038/cr.2010.99</p> <a target="_blank" href="/pubmed/20625379">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=20625379">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B63" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B63','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B64">
            <p><a name="B64"></a> Conaghan PG,  Porcheret M,  Gammon A,  Soni A,  Hurley M,  Rayman M, <em>et al</em>.: <strong> The personal impact of osteoarthritis on individuals and how they use therapies: the
                  arthritis care OA Nation 2012 Survey. </strong><p><em>Ann Rheum Dis</em> 2012,  <strong>71</strong>(Suppl 3)<strong>:</strong>584.   <a target="_blank" href="http://dx.doi.org/10.1136/annrheumdis-2012-eular.3278">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0602-8&amp;bibl=B64" onclick="popup('/sfx_links?ui=s13063-015-0602-8&amp;bibl=B64','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B65">
            <p><a name="B65"></a>Abou-Raya A, Abou-Raya S, Khadrawe T. Methotrexate in the treatment of symptomatic
               knee osteoarthritis: randomised placebo-controlled trial. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2013-204856.
            </p>
         </li>
      </ol>
   </div>
</section>
    <br class="clearall">
<div class="article-alert-signup-div">

<a class="close png_bg" id="closeHelpBox" >close</a>	
<div class="article-alert-signup rounded" > 
<span class="blurb left">Sign up to receive new article alerts from <em>Trials</em></span>

	
				<button name="articleAlertPreference.status" type="button" class="w74 right" onClick="window.location='/my/preferences'">Sign up</button>
	
</div>
</div></div>
    </div></div>
</div>


		</div>
</div>

    <hr class="hide" />
	
    

						
   
  
      
  
                  
  
                  
  
            
  
            
            


<div id="footer">

						
			<span class="views"><a id="mobile-view" href="?fmt_view=mobile">Mobile view</a> | <strong>Desktop view</strong></span>
			
	<div class="content">
    <div class="rounded ">
<div class="wrap-inner ">
        	
    <ul class="desktop">
                                                    
				        <li class="noborder"><a href="http://www.biomedcentral.com/about/tandc">Terms and Conditions</a></li>
<li><a href="http://www.biomedcentral.com/about/privacy">Privacy statement</a></li>
<li><a href="http://www.biomedcentral.com/presscenter">Press</a></li>
	<li><a href="http://www.biomedcentral.com/advertisers">Information for advertisers</a></li>
<li><a href="http://www.biomedcentral.com/about/bmcjobs">Jobs at BMC</a></li>
<li><a href="/support">Support</a></li>
<li><a href="/about/contact">Contact us</a></li>


    
    	    </ul>
    <p id="copyright">&copy; 2015 
	BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business&nbsp;Media.</p>
        </div>
</div>

	</div>

</div>
<div class="springer">
    <a href="http://www.springer.com/" target="blank"><img style="float:right; margin:0;" src="
    //www.biomedcentral.com/images/Springer_Branding_footer_logo.png" /></a>
</div>


<script>window.bmcIsMobile = "classic";</script>					    

<script>
// getElementsByClassName Polyfill
var getElementsByClassName=function(e,t,n){if(document.getElementsByClassName){getElementsByClassName=function(e,t,n){n=n||document;var r=n.getElementsByClassName(e),i=t?new RegExp("\\b"+t+"\\b","i"):null,s=[],o;for(var u=0,a=r.length;u<a;u+=1){o=r[u];if(!i||i.test(o.nodeName)){s.push(o)}}return s}}else if(document.evaluate){getElementsByClassName=function(e,t,n){t=t||"*";n=n||document;var r=e.split(" "),i="",s="http://www.w3.org/1999/xhtml",o=document.documentElement.namespaceURI===s?s:null,u=[],a,f;for(var l=0,c=r.length;l<c;l+=1){i+="[contains(concat(' ', @class, ' '), ' "+r[l]+" ')]"}try{a=document.evaluate(".//"+t+i,n,o,0,null)}catch(h){a=document.evaluate(".//"+t+i,n,null,0,null)}while(f=a.iterateNext()){u.push(f)}return u}}else{getElementsByClassName=function(e,t,n){t=t||"*";n=n||document;var r=e.split(" "),i=[],s=t==="*"&&n.all?n.all:n.getElementsByTagName(t),o,u=[],a;for(var f=0,l=r.length;f<l;f+=1){i.push(new RegExp("(^|\\s)"+r[f]+"(\\s|$)"))}for(var c=0,h=s.length;c<h;c+=1){o=s[c];a=false;for(var p=0,d=i.length;p<d;p+=1){a=i[p].test(o.className);if(!a){break}}if(a){u.push(o)}}return u}}return getElementsByClassName(e,t,n)}
</script>

						



<script type="text/javascript">
if (typeof jQuery == 'undefined') { document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.min.js' type='text/javascript'%3E%3C/script%3E")); }


document.documentElement.id = "js";

var site = {
			abbreviation: "",
	        type: "BMC_NICHE",
        portalId: "9001",
                section: "browse",
                page: "fulltext",
    		
									homePortal: "biomedcentral.com",
		
			siteShowAds: "true",
				showAds: "true",
				url: "trialsjournal.com",
			portal: false,
	        adpage_url: "trialsjournal.com/article/10.1186/s13063/015/0602/8",
        id: "10096",
	name: "Trials",
	plugins: {
		scrollable: (getElementsByClassName("scrollable").length > 0),
				flowplayer: ((document.getElementById("flowplayer") != null) || (getElementsByClassName("myPlayer").length > 0) || (document.getElementById("videoarticle") != null) || (getElementsByClassName("flowplayer").length > 0) || (document.getElementById("audio") != null) || (document.getElementById("elifeplayer") != null)),
		lightbox: ((document.getElementById("image-highlight") != null) || (getElementsByClassName("lightbox").length > 0)),
		thickbox: (getElementsByClassName("thickbox").length > 0),
		altmetric: ((document.getElementById("altmetric") != null) || (getElementsByClassName("altmetric").length > 0))
	}
	
};



if(typeof quoteSearchUri == "undefined") { quoteSearchUri=null; }
</script>



        <script type="text/javascript" src="http://www.bmcimg.com/javascript/journals/behaviours-0.js"></script>






		<script>
	if (site.plugins.scrollable == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.scrollable-1.0.1.min.js' %3E%3C/script%3E")); 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.tools.min.js'%3E%3C/script%3E"));
	}

	if (site.plugins.flowplayer == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/flowplayer-3.2.6.min.js'%3E%3C/script%3E"));
	}

	if (site.plugins.lightbox == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/browse_imagehighlight.js'%3E%3C/script%3E"));
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.colorbox.js' %3E%3C/script%3E"));
	}

	if (site.plugins.thickbox == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/thickbox-compressed.js' %3E%3C/script%3E"));
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/thickbox-flashhidden-patch.js' %3E%3C/script%3E"));
	}
	</script>





            <script type="text/javascript" src="http://www.bmcimg.com/javascript/plugins/jquery.fancybox-1.3.1.pack-0.js"></script>
            <script type="text/javascript" src="http://www.bmcimg.com/javascript/plugins/jquery.debug-0.js"></script>
                      <script type="text/javascript" src="http://www.bmcimg.com/javascript/email_preferences/email_preferences-0.js"></script>
                <script type="text/javascript" src="http://www.bmcimg.com/javascript/articles/articles-0.js"></script>
		<div id="fb-root"></div>











        <script type="text/javascript" src="/javascript/plugins/jquery.tagcloud.min-0.js"></script>




<!--[if lte IE 6]>
            <script type="text/javascript" src="/javascript/plugins/DD_belatedPNG_0.0.8a-0.js"></script>
    <script type="text/javascript">
        DD_belatedPNG.fix('.png_bg, ul.primary-nav li a, ul.primary-nav li a span, ul.secondary-nav li a, ul.secondary-nav li a span, ul li i, .plus-button, .facebook, .twitter, .fancy-bg, #fancybox-close');
    </script>
	                <link rel="stylesheet" type="text/css" href="http://www.bmcimg.com/css/hacks/ie6-0.css"/>
    <![endif]-->

<!-- Claudia Whitcombe wanted this comment here -->

       <div class="hide">
      <dl class="google-ad" id="x96banner">
        <dt style="display: block;" class="hide">
          <a class="skyscraper-ad" href="http://www.biomedcentral.com/advertisers/digital_advertising">Advertisement</a>
       </dt>
        <dd>
          <!-- OAS AD 'x96' begin -->
          <script type="text/javascript">
            OAS_AD('x96');
          </script>
        </dd>
      </dl>
    </div>  
    
</body>
</html>

